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CHAPTER 1: INTRODUCTION 
1.00 Glucose  
Natural glucose has the D-configuration (derived from D-glyceraldehyde). With a 
chemical formula C6H12O6, D-glucose is a six-carbon aldehyde attached to five hydroxyl 
groups in the open chain form. The intramolecular nucleophilic addition of the C-5 hydroxyl 
group and the C-1 aldehyde forms a 6-membered hemiacetal ring, which is called D-gluco-
pyranose. D-gluco-furanose is the 5-membered hemiacetal ring generated when the C-4 
hydroxyl group attacks at C-1 aldehyde (Figure 1). The ring closure generates two 
stereoisomers at C-1 known as the α and β anomers. When drawn as Fischer's projection, the 
α isomer has anomeric hydroxyl group on the same side as the hydroxyl group of the C-5 
stereogenic center, whereas the β anomer places the anomeric hydroxyl at the opposite side to 
the hydroxyl at the C-5 stereogenic center (Figure 1).  
 
Figure 1. Structures of α,β-D-glucopyranose and α,β-D-glucofuranose 
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1.10 β-D-Glucans 
1.11 Structure and origin 
      Glucans are the polysaccharides consisting of multiple glucose units. Starch, the most 
common carbohydrate in human diet, is a mixture of glucans consisting mainly of α (1 → 4) 
linked D-glucose units. Cellulose, the most abundant organic polymer on earth,1 is a glucan 
consisting of a large number of β (1 → 4) linked D-glucopyranose units. β-(1 → 3)-D-glucans 
are natural polysaccharides consisting of β (1 → 3)-linked D-glucopyranose units and are the 
major constituents of many fungal and yeast cell walls.2 β-D-Glucans are also abundant in 
cereals and bacteria.3 Their structures vary according to their origin; β-(1 → 3)-D-glucans can 
be linear, as in the case of curdlan (produced by bacteria Alcaligenes faecalis), laminarin 
(polysaccharide found in brown algae). Others can be branched, as in the case of schyzophillan 
(extracellular polysaccharide of the fungus Schizophyllum), and lentinan (a component of the 
cell wall of the Japanese fungus Lentinula edodes). These glucans differ from each other in the 
number and position of branches (positions 2, 4 or 6), which depends on their origin (Figure 
2). 3 
 
Figure 2. Structure variability of β-(1→3)-D-glucans according to their origin 
1.20 Biological activity 
1.21 Introduction of the immune system  
When the body encounters an invading pathogen, the innate immune system is the first 
line of defense.4 Phagocytic cells can kill invading pathogens nonspecifically. Monocytes and 
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macrophages together make up one of the three types of phagocytes in the immune system. 
The others being the granulocytes (neutrophils, eosinophils and basophils) and dendritic cells. 
Macrophages perform several different functions in the innate immune responses. An 
important function is to engulf and kill invading microorganisms; This process is known as 
phagocytosis. Pattern recognition receptors (PRR) on the surface of phagocytic cells recognize 
pathogen-associated molecular patterns (PAMP) of microorganisms. After recognition, a 
microorganism is trapped in a phagosome which then fuses with a lysosome to form a 
phagolysosome, within which enzymes and toxic peroxides digest the microorganism. The 
recognition and interaction of PAMPs by PRRs is a critical step in the immune response. It 
allows the innate immune system to distinguish self (the body) and nonself (pathogen). After 
phagocytosis, macrophage will activate T lymphocyte cell by presenting antigen derived from 
pathogen. For this reason, macrophage is also known as antigen-presenting cell (APC). 
Activated APC bearing pathogen antigens are delivered to the lymphoid tissues to activate the 
adaptive immune response. For example, immature dendritic cells are stimulated by 
recognition of the pathogen and migrate through the lymphatics to regional lymph nodes. They 
arrive as fully mature non-phagocytic dendritic cells that express antigen and co-stimulatory 
molecules to activate naive T cell thus initiating the adaptive immune response. 
1.22 Immunostimulating effect of β-(1→3)-D-glucans 
      The immunostimulating properties of β-(1→3)-D-glucans were first discovered in the 
1960’s and extensive studies on them have continued ever since.5 Binding of β-(1→3)-D-
glucans to the PRR of macrophages will activate phagocytosis and several other process 
including increased chemokinesis, chemotaxis and migration of macrophages to pathogen.6 
 4 
There are many medicinal applications of β-(1→3)-D-glucans and some of them have reached 
Phase I/II in clinical trials. 7  
1.221 Effect of β-(1→3)-D-glucans on cancer 
      Over the last 25 years, Japan has used several mushroom-derived β-glucans in cancer 
patients. For example, lentinan8 is used in the treatment of colorectal and gastro-intestinal 
cancers, whereas schizophyllan9 is used for the treatment of stomach and uterine cancers. 
Commercially available β-glucans have been applied to patients receiving chemotherapy. 
Clinical studies of β-glucans have shown that they prolong patients' lives and improve their 
quality of life.7 Indeed, the administration of these glucans allows a better recovery of the 
immune system, after damage from exposure to radiation. In addition, the stimulated 
production of macrophages and therefore of phagocytosis by glucans, is an important factor in 
oncology, since macrophage limit the growth of tumors. 
1.222 Effect of β-(1→3)-D-glucans on infections 
      In 1994, Alpha-Beta Technologies conducted a series of trials, which showed that 
surgical patients who received β-D-glucan had significantly reduced infections and a decrease 
in the use of antibiotics.10 Many β-D-glucans are also effective against bacterial infections. The 
lentinans reduce infections in rats caused by Mycobacterium tuberculosis by increasing the rate 
and effectiveness macrophages in vivo.11 PGG-glucan, a homopolymer of glucose derived from 
the cell wall of the yeast Saccharomyces cerevisiae has a β - (1 → 3) backbone and side chain 
branching at C-6. It increases the anti-infectious activity of leukocytes in vitro and in vivo, and 
effectively suppresses infections caused by Staphylococcus aureus,12 including cell lines 
resistant to certain antibiotics such as β-lactams (including methicillin), improving patient 
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survival by 80%.13 Overall, there is abundant evidence to demonstrate that the immune system 
can be stimulated by β - (1 → 3)-D-glucans.  
1.23 β-(1→3)-D-glucan receptors  
      Several receptors of β-glucans have been identified: scavenger receptors,14 
lactosylceramide,12 Toll-like receptors (TLRs),15  complement receptors 3 (CR3) 16-17and 
Dectin-1.18 Among these receptors, CR3 and Dectin-1 are the most important receptors. 
1.231 Complement receptor 3 (CR3) 
In 1987, the Ross group identified Complement Receptor 3 (CR3) as a receptor for β-
D-glucans.19 Complement Receptor 3 is widely expressed on immune cells including 
leukocytes, macrophages and NK cells. CR3 is also known as αMβ2-integrin because it is made 
up of two protein subunits: the αM unit CD11b and the β2 unit CD18.20 β-glucans can bind with 
high affinity to the lectin site and the overlapping I-domain of CD11b. However, β-glucan 
binding alone cannot activate the immune response. A simultaneous binding of iC3b-opsonized 
molecules and β-glucan on CR3 is required to trigger the immune system.21 
1.232 Dectin-1 
      Dectin-1 is a C-type lectin widely expressed on macrophages, neutrophils and dendritic 
cell surface membranes. It has been found to be the major receptor for β-(1 → 3)-D-glucans. 18, 
22-23 The high affinity to β-(1 → 3)-D-glucan comes from the carbohydrate binding domain 
(CRD) on Dectin-1.24 To understand the interaction between β-glucans and Dectin-1, Ohno 
and co-workers prepared 32 point mutants with mutations in the CRD of Dectin-1 and analyzed 
their binding with SPG (a 1,6-branched 1,3-β-glucan from S. commune). They found that 
mutations at Trp 221 and His 223 resulted in a decrease in β-glucan binding.24 In 2007, Brown 
 6 
and co-workers acquired the crystal structure of murine Dectin-1.25 The crystal structure 
reveals a shallow surface groove between Trp 221 and His 223. Further analysis of the 
electrostatic potential surface reveals the binding groove between Trp 221 and His 223 doesn’t 
have any imbalance of charge. This result indicating that β-glucan binding is driven mainly by 
vander waals interactions.  
1.24 Saturation transfer difference NMR (STD-NMR) study  
Saturation transfer difference NMR is a spectropic technique to study the interactions 
between the large molecule (receptor) and small molecule (ligand). The protein was selectively 
saturated and the saturation is transferred to the ligand via spin diffusion through the 
intermolecular nuclear overhauser effect.26  
To precisely identify the binding epitope of β-(1 → 3)-D-glucan with its receptors, saturation 
transfer difference (STD) NMR experiments were performed on laminarin (oligo- β-(1 → 3)-
D-glucan found in brown algae) in the presence of Dectin-1(Figure 3). In this study, the H-1 
was selected as internal standard and the STD-effect was set as 100%. The α-face protons H-
3, H-5 display a 142% STD-effect, whereas H-2 and H-4 protons only display 50% STD-effect. 
These results indicate that the binding affinity is mainly from the hydrophobic interactions 
between the α face of glucan and the hydrophobic groove of Dectin-1.27  
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Figure 3. Schematic representation of STD effects between β-(1 → 3)-D-glucan and Dectin-1 
1.30 Synthesis of β-(1 → 3)-D-glucans 
      β-glucans isolated from nature show great structural variability. For example, the 
Vetvicka laboratory has tested the immunological effect of more than 110 β-glucans from nine 
countries and has found considerable biological variability. 28-29 This variability arises because, 
first, the structure of the cell walls from which the glucans are isolated varies with growth 
conditions; second, many different isolation procedures and extensive chromatographic 
purification give a variety of β-glucans.30 Thus obtain reliable and reproducible results, the 
biological study of β-glucans must be performed with homogeneous synthetic β-glucans.  
Since 1993, several strategies have been developed to synthesize the linear β-(1 → 3)-D-
glucans (Table 1). 31 Two strategies to synthesize pure β-glucan oligosaccharides are used: a) 
Linear approach using monosaccharides as building blocks where chain length increases one 
unit at one time. b) Convergent approach using short oligosaccharides as building blocks where 
each glycosylation doubles the chain length.  
Table 1. Linear β-(1→3)-D-glucans synthesized to date.     
 
O
OHO
OH
HO
O
O
HO
OH
OH
OH
H
n
n = 19 to 32
Dectin-1
142% 142% 100%
50% 50%
H
H
H
H
H
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Reference 
 
Reference 
n = 1 
1993, Takeo et al.32 
2005, Jamois et 
al.33  
2011, Adamo et al. 
34 
2013, Jong et al.35 
  n = 6 
1993, Takeo et 
al.32 
2010, Tanaka et 
al.36 
2015, Liao et 
al.37 
n = 2 
1993, Takeo et al.32 
2003, Zeng et al.38 
2005, Jamois et 
al.33 
  n = 8 
2015, Liao et 
al.37 
n = 3 
1993, Takeo et al.32 
2005, Huang et 
al.39 
2005, Jamois et 
al.33 
  n = 10 
2010, Tanaka et 
al.36 
2013, Weishaupt 
et al.40 
2015, Liao et 
al.37 
n = 4 
1993, Takeo et al.32 
2009, Mo et al.41 
2011, Adamo et 
al.34 
2015, Liao et al.37 
2015, Elsaidi et 
al.42 
  n = 12 2010, Tanaka et 
al.36 
n = 5 1993, Takeo et al.32   n = 14 2010, Tanaka et 
al.36 
                                                                           
1.31 Linear approach 
      In a typical example of the linear approach, Vetvicka and co-workers synthesized tri, 
tetra and pentasaccharides using an iterative deprotection-glycosylation process (Scheme 1).33 
In this process monosaccharide 1 acted as both donor and acceptor to elongate the chain. The 
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3-ONAP group of monosaccharide 1 was selectively deprotected by DDQ to serve as acceptor. 
The donor 1 was activated by NIS / TESOTf for glycosylation to give the disaccharide. The 
Benzoyl group at C-2 was installed for the neighboring group participation leading to β-
selectivity. After glycosylation, the oligosaccharides were deprotected using Zemplén 
deacetylation and catalytic hydrogenolysis to afford the corresponding free oligosaccharides. 
It was found that the synthesized laminaritetraose and laminaripentaose have similar 
immunostimlatory effects to the natural β-(1→3)-glucan phycarine. 33 
 
Scheme 1. β-(1 → 3)-D-glucan synthesis by iterative glycosylation process 
1.32 Convergent approach 
      The convergent strategy improves the “n+1” elongation process into an “n+n” process 
by employing short oligosaccharides as building blocks. In 2012, Takahashi and co-workers 
synthesized linear hexadecasaccharides (16 units) employing a tetra-saccharide as key building 
block.43 In 2015, the Guo lab accomplished the convergent synthesis of octa-, deca-, and 
dodeca- β-(1→3)-D-glucans. The synthesis was accomplished with preactivation-based 
iterative glycosylation using p-tolylthioglycosides as donors and disaccharide 4 as key building 
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block (Scheme 2). The synthesized oligosaccharides were coupled with a carrier protein 
keyhole limpet hemocyanin (KLH) to form a new glycoconjugate vaccine. These conjugates 
successfully provoked protective immunity against Candida albicans infections. 37 
 
Scheme 2. Guo and co-workers’ convergent synthesis of linear β-(1→3)-D-glucans 
1.33 Solid phase oligosaccharide synthesis (SPOS) 
      Traditional solution phase oligosaccharide synthesis has several limitations for longer 
saccharide synthesis. For example, the need for separation of side products after each 
glycosylation, the poor solubility of longer oligosaccharides, low stepwise yields and time-
consuming protecting group manipulation. Solid phase oligosaccharide synthesis provides a 
more efficient way of oligosaccharide synthesis. Automated solid phase synthesis of 
oligopeptides and oligonucleotides have made great contributions to the progress in proteomics 
and genomics research. 44-45 The automated oligosaccharide synthesis, however, still leaves 
much to be accomplished.46  Many laboratories have realized the solid phase oligosaccharide 
synthesis.47 In 2013, Seeberger’s group developed the automated solid phase synthesis of a 
linear β-(1→3)-D-glucan with 12 glucose units.40 The glycosylation method employs a 
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glucosyl phosphate as donor with a pivaloyl group in the C-2 hydroxyl group and an orthogonal 
protecting group at C-3 (Fmoc) (7). The first glycosylation connected 7 to the Merrifield resin 
photolabile linker 8. After glycosylation, the Fmoc group at C-3 was selectively cleaved by 
piperidine in DMF and ready for the next glycosylation. This two-step process was repeated 
12 times for elongation before the Merrisfield resin linkage was cleaved under UV irradiation 
to give the protected dodecasaccharide 9. Global deprotection gave the final product 10 in 4.6% 
overall yield after 25 steps, with an average yield of 88% per step (Scheme 3). 
 
Scheme 3. Seeberger’s automated solid phase synthesis of oligo-β-(1→3)-D-glucan  
2.00 Glycan mimetics  
2.10 The challenge of oligosaccharide synthesis 
      The other two major biomolecules, oligopeptides and oligonucleotides, are linear 
biopolymers connected with amide and phosphodiester bonds. Unlike templated peptide and 
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nucleotide synthesis, oligosaccharide synthesis encounters two major challenges: A) 
Regioselectivity of different hydroxyl groups. B) Stereoselectivity of glycosidic bond 
formation, also branched structures. Furthermore, the complexity of oligosaccharides is 
enormously greater than in the oligonucleotides and oligopeptides. For example, in the case of a 
hexanucleotide there are a total of 46 (=4096) different structures possible and 206(=64 million) for 
hexapeptide. In the case of hexasaccharides, based on the 10 mammalian monosaccharides, 
regioisomers and two different stereoisomers, it was calculated that 192 billion different structures 
are theoretically possible.48 On one hand, oligosaccharide synthesis is still challenging by 
conventional organic synthesis, and only few laboratories in the world could accomplish long 
oligo-β-(1→3)-D-glucans synthesis (Table 1). On the other hand, as the hydrophilic nature of 
oligosaccharides make them poor ligands to receptors, and carbohydrate protein interactions 
are dependent on multivalent interactions.49 In addition, many natural oligosaccharides are 
easily degraded by glycosidase, which makes them poor drug candidates. Our projects are 
designed to provide solutions to these problems by modifying the original β-(1→3)-D-glucan 
structure to achieve 3 goals. A) Higher synthetic efficiency: Modification of the structure could 
allow development of a simple and efficient methods for connecting the different units and 
would allow access to long-chain polymers, ideally on solid support. B) Higher binding affinity 
to receptors: Rather than working on synthesizing long oligosaccharide, we seek to redefine 
the problem and utilize new approaches. Thus, by preparing glycan mimetics with short chain 
lengths we hope to reproduce the biological activity of natural long oligosaccharides. For 
example, natural glucans are hydrophilic and through modification we could increase the 
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hydrophobicity of the oligosaccharide thus increasing the binding affinity to receptors. C) 
Higher stability: Natural glucans are labile to enzymatic degradation. Consequently, by 
modifying both the exocyclic and endocyclic oxygen of glycosidic bonds we could improve 
glycosidase inhibition by increasing the stability of oligosaccharides (Figure 4). In summary, 
our goal is to design and synthesize β-(1→3)-D-glucan mimetics that have increased 
interactions with receptors, improved biological activities and simplified oligomer synthesis. 
 
Figure 4. Glycan mimetics with exocyclic and endocyclic oxygen modification  
2.20 Precedent β-(1→3)-D-glucan mimetics 
2.21 Hydroxylamine based β-(1→3)-D-glucan mimetics 
 
Figure 5. Chemical structure of oligomeric hydroxylamine-linked β-(1 → 3)-D-glucan 
mimetics 
      The Crich laboratory designed and synthesized β-(1→3)-D-glucan mimetics based on 
imino sugars linked through a hydroxylamine N-O bond (Figure 5).50 It is known the barrier 
to inversion at nitrogen atom in trialkyl hydroxylamines is lower than that in simple protonated 
amines at approximately 15 kcal/mol. Thus, hydroxylamines lack barriers hence is not 
sufficient to prevent rapid inversion at room temperature.51-53 Therefore, as an analogue of 
anomeric C-O bond, the hydroxylamine N-O bond doesn’t have a preferential configuration. 
HO N
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They developed a ring-closing double reductive amination method to prepare the 
hydroxylamine mimetics.54 
      The enantiomerically pure cyclopentadiene-derived mesyloxy epoxide 11 was 
subjected to ring opening with potassium hydroxide and acetophenone oxime in hot DMF to 
give the desired o-cyclopentenyl oxime 12 in 34% yield. Subsequent benzylation and 
elimination was completed in one pot to give cyclopentene derivative 13 in 99% yield. 
Cleavage of the oxime with 2,4-DNP catalyzed by sulfuric acid gave hydroxylamine 14 in 74% 
yield (Scheme 4). The hydroxylamine 14 was protected as its N, N-diBoc derivative 15 by a 
standard carbamate forming reaction in 97% yield. Ring opening of N, N-diBoc cyclopentenyl 
hydroxylamine 15 using catalytic osmium tetroxide and sodium metaperiodate to give a 
dialdehyde 16 with a protected ONH2 in 49% yield. Treatment of compound 19 with catalytic 
amount of osmium tetroxide and NMO gave a diol intermediate which was immediately 
cleaved by sodium metaperiodate to give the dialdehyde 20 in 80% yield (Scheme 4). 
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Scheme 4. Dialdehyde synthesis by oxidative cleavage of cyclopentene derivatives 
      Dialdehyde 16 was subjected to ring-closing double reductive amination with allyl 
hydroxylamine HCl salt to give N,N-diBoc protected hydroxylamine intermediate 17. N,N-
diBoc protecting group was removed under acidic condition to give free hydroxylamine 18 in 
88% yield (Scheme 5).  
 
Scheme 5. Monomer synthesis by oxidative cleavage and double ring closing reductive 
amination 
      Hydroxylamine intermediate 18 was subjected to another reductive amination with 
dialdehyde 20 to give benzyl protected dimeric mimetic 21 in 30% yield. The benzyl group 
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was deprotected by BCl3 to give the hydroxylamine based disaccharide mimetic 22 (Scheme 
6). 
 
Scheme 6. Synthesis of dimeric hydroxylamine based β-(1 → 3)-D-glucan mimetics 
      The Trisaccharide mimetic 25 was also synthesized from compound 18. The N,N-diBoc 
protecting group of 18 was removed under acidic condition and the intermediate was subjected 
to double reductive amination with dialdehyde 16 to give the dimeric intermediate 23 in 53% 
yield. The N,N-diBoc protecting group were deprotected under acidic condition to give free 
hydroxylamine, which was subjected to double reductive amination with dialdehyde 20 to give 
benzyl protected trimeric hydroxylamine 24 in 7% yield. The benzyl protecting group was 
removed by BCl3 in DCM to give the hydroxylamine based trisaccharide mimetic 25 (Scheme 
7).  
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Scheme 7. Synthesis of trimeric hydroxylamine based β-(1 → 3)-D-glucan mimetics 
      To evaluate the binding affinity of the hydroxylamine to CR3 and Dectin-1, the 
Vetvicka laboratory tested the mimetics’ ability to inhibit anti-CR3 and anti-Dectin-1 
fluorescein isothiocyanate (FITC) conjugated antibody staining of human neutrophils and 
mouse macrophages. For comparison purposes, monohydroxylamines 26 and 27 were also 
screened. In terms of CR3 binding affinity, incubation of a 0.1μg / ml solution of β-(1→3)-
dimer mimetic 22 and β-(1→3)-trimer mimetic 25 caused 26% and 34% decreases in inhibition 
of staining human neutrophils, while the anomeric β-(1→6)-dimer mimetic 26 and 27 
decreases were 19% and 22% (Table 2). In terms of Dectin-1 binding affinity, incubation of a 
0.1μg/ml solution of β-(1→3)-trimer mimetic 25 with mouse macrophage led to 43% decrease 
in the inhibition of anti-dectin-1-FITC staining of mouse neutrophils. Under the same 
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conditions, the β-(1→3)-dimeric mimetic 22 caused 28% decrease in inhibition of antibody 
staining whereas the β-(1→6)-dimer mimetics 26 and 27 caused 29% and 21% decreases 
respectively (Table 2). These results indicate that binding of the hydroxylamines to the lectin 
domains of both CR3 and Dectin-1 is correlate to length and linkage.  
Table 2. Percentage inhibition of anti-CR3 and anti-Dectin-1-FITC antibody staining of 
neutrophils, macrophages by 0.1μg/mL substrate. a Mean ± SD 
                                                                            
 
Compound 
 
Linkage-
mimicked 
 
Oligomer 
NO. 
% inhibition of 
anti-CR3-FITC 
staining   
human 
neutrophilsa 
% inhibition of 
anti-dectin-1-
FITC staining of 
mouse 
neutrophilsa 
26 1→ 6 dimer 19.7±1.7 29.3±2.2 
27 1→ 6 dimer 22.3±1.9 20.6±2.1 
22 1→ 3 dimer 26.4±2.7 28.2±2.9 
25 1→ 3 trimer 34.2±3.3 43.1±3.5 
     
                                                                              
      Hydroxylamine based β-glucan mimetics 26, 27, 22, 25 (10 μg / mL) were also tested 
for their ability to stimulate phagocytosis of synthetic polymeric 2-hydroxyethyl methacrylate 
microspheres by human macrophage-like RAW 264 cells.55 Commercial yeast derived 
insoluble whole glucan particles WGP (hollow spheres of long polymers of primarily β-(1→ 
3)-D-glucan) were used as reference (Table 3). The result indicates that the β-(1→3)-trimer 
mimetic 25 could stimulate 16% of phagocytosis, which is more effective than the β-(1→6)-
dimer mimetic 26, 27 and 22. It is notable that the level of phagocytosis stimulated by the β-
(1→3)-trimer mimetic 25 was more than 50% of that induced by WGP. These results indicate 
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that the hydroxylamine glucan mimetics have good immunostimulating ability even at short 
length. 
Table 3. Percentage stimulation of phagocytosis. a Mean ± SD 
                                                                                 
Compound Linkage 
mimicked 
Oligomer 
NO. 
% stimulation of phagocytosis 
(RAW 264 macrophages, 10μg / 
mL, 24h) a 
26 1→ 6 dimer 6.7±0.9 
27 1→ 6 dimer 4.1±0.5 
22 1→ 3 dimer 7.8±1.1 
25 1→ 3 trimer 16.6±2.0 
WGP 1→ 3 Insol polymer 30.1±2.8 
                                                                              
2.22 β-(1→3)-D-Glucan with thiolinkage 
 
Figure 6. Chemical structure of oligo-β-(1 → 3)-D-glucans with thiolinkage 
      Thioglycoside, in which the glycosidic oxygen atom is replaced by sulfur, is known to 
be more stable to acidic or enzymatic hydrolysis. Moreover, this modulation has only minor 
impact on overall conformation. Based on these facts, the Vetvicka laboratory designed 
thioglycosidic-linked oligo-β-(1→3)-glucans families (Figure 6).56-57 The synthesis started 
from peracetylated laminaribiose 28 and laminaritriose 29. Treatment of the compound 28 and 
29 with 33% HBr / HOAc afforded the anomeric bromide 30 and 31 in 86% and 80% yield 
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respectively. The anomeric bromide was substituted by thioacetate anion to give the β-
glucopyranosyl thioacetate 32 and 33 which were subjected to selective deacylation to give the 
anomeric thiol 34 and 35 in 85% and 68% respectively. In the presence of the crown ether 
Kryptofix 21 and sodium hydride, anomeric thiol was activated to replace the triflate group of 
3-O-trifluoromethanesulfonyl-1,2;5,6-di-O-isopropylidene-α-D-allofuranose. Compound 34 
and 35 were coupled with triflate 36 to give the disaccharide intermediates 37 and 38 in 86% 
and 71% respectively. After acidic hydrolysis, acetylation and Zemplén deacetylation, the 
intermediates 37 and 38 were deprotected and acetylated to give trisaccharide 39 and 
tetrasaccharide 40 in 70% and 51% respectively. Final Zemplén deacetylation and Sephadex 
G-25 gel purification gave the thio-linked β-(1 → 3)-D-glucan mimetics 41 and 42 (Scheme 
8).  
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Scheme 8. Synthesis of oligo-β-(1 → 3)-D-glucans with thio-linkage 
      The same protocol was applied to synthesize trimeric mimetic 43 and tetrameric 
mimetic 44. These four compounds were evaluated by Vetvicka laboratory. First, the 
phagocytic abilities were tested, including their effect on stimulation of peritoneal 
macrophages and peritoneal blood neutrophils and monocytes. A strong immunostimlating 
effect was observed from compound 42, 43 and 44. To determine if the samples influence 
cytokine production, they tested the production of IL-2 by splenocytes and the levels of IL-1β 
and TNF-α in peripheral blood. The compounds 41, 43 and 44 stimulated the production of 
tested cytokines and 44 is the most active mimetic. Finally, theses samples were assessed for 
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their potency in inhibiting colon CSC-mediated tumor formation and/or metastasis. It is 
noteworthy that the β-(1 → 3)-thioglucan 43 which has two thioglycosidic linkages, 
demonstrated good anti-cancer activity. Compound 43 significantly suppressed spheroid 
formation and proliferation of colon cancer stem-like cells from human colon adenocarcinoma, 
more effective than the natural laminarin. These promising results indicate the presence of 
sulfur atom is beneficial for biological activity.  
3.00 Sulfur in medicinal chemistry 
      Sulfur is the 5th most abundant element on earth. Our body consists 0.25% of sulfur, 
which is crucial for many biological processes.58 Two amino acids, cysteine and methionine 
and two vitamins (biotin and thiamine) are organosulfur compounds. The disulfide bond is a 
common linkage in proteins that is crucial to the protein structures. Sulfur-aromatic interactions 
were critical in chemical and biological process with many examples in the context of protein-
protein and protein-ligand interactions.59 The preferential conformation of a bridged 
oxathiolane compound gave the evidence for sulfur-aromatic interactions.60 Sulfur’s history in 
drugs dates to ancient Egypt, where people used sulfur as an antiseptic. Today, the organosulfur 
compounds have extraordinary impact on medicinal chemistry. In the U.S. 40% and 25% of 
the top 20 drugs by retail sales and prescription respectively contain sulfur.61 In addition, a 
survey of the top 200 brand name drugs by total U.S. prescriptions in 2011 revealed that 24.8% 
of drugs contain sulfur61. Accoridng to statistics (Figure 7), over the 12 major diseases 
categories, sulfur containing drugs is 50% more than fluorine in the Anti-infectives category. 
In Cardiovascular and Musculoskeletal categories, sulfur containing drugs comprises 60% 
more than the fluorine containing drugs.61  
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Figure 7. Percentage composition of sulfur-containg and fluorine-containing pharmaceuticals 
that comprise each of the 12 representative disease categories 
4.00 Conclusion 
 
Figure 8. Chemical structure of oligomeric β-(3 → 5)-dithio-D-glucan mimetics 
      Over the past few years, great effort was spent on understanding and improving the 
immunostimulating effect of β-(1 → 3)-D-glucan.62 It was demonstrated that laminaripentaose, 
a five-membered oligo-β-(1→3)-D-glucan, could also trigger immunostimulating activity 
equivalent to that of laminarine.33 X-Ray crystallographic studies of recombinant Dectin-1 
have revealed a hydrophobic pocket lined by the side chains of Trp 221 and His 223.25 STD-
NMR experiments revealed that laminarin binding through vander waals interaction of the α-
face of terminal pyranose rings (at both the reducing and nonreducing ends) with the Trp 221 
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and His 223 of the Dectin-1 binding domain. 27, 63 Crich and coworkers prepared hydroxylamine 
analogues of β-glucan. Interestingly, although the oligomer is short, they have very good 
biological activity. The good activity of these small analogues is possibly because of the 
increased hydrophobicity of the synthetic 2-deoxy hydroxylamine mimetics. These studies and 
preliminary results proved the concept of principle that the increased hydrophobicity of the β-
glucans increased their binding affinity to CR3 and Dectin-1. More importantly, 
hydroxylamine analogues of β-glucan provide an unprecedented example using hydroxylamine 
N-O bond mimic glycosidic C-O bond, the fact that low barrier to inversion of hydroxylamine 
nitrogen lone pair helps it mimic both α and β glycosidic bond. Based on these studies, we 
hypothesized that replacement of both the exocyclic oxygen and endocyclic oxygen atom by 
more lipophilic sulfur can increase the noncovalent interactions between β-(1 → 3)-D-glucan 
mimetics and the receptors. Second, the modification with endocyclic and exocyclic sulfur can 
resist the acidic and enzymatic hydrolysis to the largest extent. It is very likely that these 
modifications will give excellent β-(1 → 3)-D-glucan mimetics. Therefore, we designed the 
oligo-3,5-dithio-β-D-glucopyranoside as β-(1 → 3)-D-glucan mimetics (Figure 8).  
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CHAPTER 2: DESIGN AND SYNTHESIS OF OLIGO-(3,5-DITHIO-β-D-
GLUCOPYRANOSIDES) AS β-(1 → 3)-D-GLUCAN MIMETICS 
1.00 Introduction 
      R. Schmidt’s review64 about thioglycoside synthesis provide many examples of 
thiooligoglycoside synthesis. There are three different methods to synthesize thioglycosides: 1) 
Base promoted thioglycosylation; 2) Anomeric thiol alkylation; 3) Acid catalyzed 
thioglycosylation.  
 
Figure 9. Illustration of 3 methods to build up thio-linked oligosaccharide 
1.10 Example of base promoted S-glycosylation: S-analogue of Sialyl Lewis X synthesis  
      Sialyl Lewis X is a tetrasaccharide carbohydrate that is usually attached to O-glycans 
on the cell surface. Schmidt and co-workers65 performed base promoted S-glycosylation to 
 26 
synthesize Sialyl Lewis X thio-analogue. In the presence of Kryptofix 21 in THF, the thiol of 
46 substituted the anomeric chloride of compound 45 to give thioglycoside 47 in 75% yield. 
The anomeric siloxyl group was deprotected and acetylated to give compound 49 in 85% yield 
and the anomeric carbon of disaccharide 49 was brominated to give compound 50 in 95% yield. 
The anomeric bromide of 50 was substituted by thiol of 51 to give tetrasaccharide 52 in 70% 
yield. 
 
Scheme 9. Synthesis of the S-analogue of Sialyl Lewis X via base promoted S-glycosylation 
1.20 Example of base promoted anomeric thiol alkylation: synthesis of 4-
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thiomaltooligosaccharide 
 
Scheme 10. The convergent synthesis of 4-thiomaltooligosaccharide 
      Driguez and co-workers66synthesized the 4-thiomaltopentaoside by anomeric thiol 
alkylation. The synthetic route is an iterative process and the α-(1→4)-S-linkage was built up 
by SN2 substitution of C-4 triflate from anomeric thiol. Coupling of compound 53 with 
compound 54 afforded the triphenylmethyl 1,4-dithio-α-maltoside 55 in 78% yield. The 1-S-
triphenylmethyl group was deprotected in a two steps process. First, S-trityl group was cleaved 
by PhHgOAc in the presence of hydrogen sulfide. Then, the anomeric thiol was converted to 
S-acetyl to give compound 56 in 59% yield. Compound 57 was coupled with triflate 54 to give 
the trisaccharide 57 in 78% yield. The same two steps procedure to converted the S-
triphenylmethyl into S-acetyl group was applied to 57 afforded 58 in 96% yield. In a 
convergent approach, coupling of 58 with disaccharide triflate 59 afforded thio-malto-
pentasaccharide 60 in 68% yield.  
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1.30 Examples of acid catalyzed S-glycosylation  
1.31 Tf2O / DTBMP promoted S-glycosylation using glucosyl sulfoxide donor  
      Crich lab67 developed the β-selective glycosylation in which anomeric S-phenyl 
sulfoxide acts as glycosylation donor and Tf2O / DTBMP as the activator. They applied this 
method in S-glycosylation. The sulfoxide donor 61 was activated by Tf2O / DTBMP at -78 °C 
to 0 °C, the generated mannosyl triflate intermediate was substituted by thiol acceptor 62 to 
give disaccharide 63 with β thio-glycosidic linkage (Scheme 11). 
 
Scheme 11. β-selective S-glycosylation of mannosyl sulfoxide 61 and thiol acceptor 62. 
      Application of this method to 5-thio-glucose was not reported because of the lack of 
selectivity in the oxidization of exocyclic and endocyclic sulfur (Scheme 12). 68  
 
Scheme 12. Oxidation of ethyl β-1,5-dithioglucopyranosides with m-CPBA. 
1.32 TESOTf promoted S-glycosylation using glucopyranosyl trichloroacetimidate 
donor  
      S-glycosylation using acid catalyzed trichloroacetimidate donor and thiol acceptor was 
studied by Pinto and co-workers.69 In the glycosylation of the thiol 67 with 2,3,4,6-tetra-O-
acetyl-α-D-glucopyranosyl trichloroacetimidate 68. When 0.14 equivalent of the catalyst 
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TESOTf were added, both glycosylation product 69 were formed in 59% yield with an α and 
β ratio of 1: 2.3 (Scheme 13). 
 
Scheme 13. TESOTf catalyzed S-glycosylation with 5-thio-glucopyranosyl 
trichloroacetimidate 68 as the donor compound 67 as the acceptor. 
      They also studied the TESOTf promoted glycosylation of 5-thioglucopyranosyl 
trichloroacetmidate 74 with 4-OH, 4-SH and 4-SeH groups of glucopyranoside acceptors 70-
73 (Scheme 14) . 70  
 
Scheme 14. TESOTf promoted S-glycosylation using 5-thio-glucopyranosyl 
trichloroacetimidate 74 as the donor with glucose with 4-OH, 4-SH and 4-SeH (70-73) as the 
acceptors.  
      The glycosylation of acceptor 70 with glucopyranosyl trichloroacetimidate 74 activated 
by triethylsilyl triflate (donor : acceptor : promotor = 1:2:0.1) afforded exclusively α-
disaccharide 75 in 87% yield (Table 4, Entry 1). When glycosylation was performed with the 
same substrate but different ratio (donor : acceptor : promotor = 2:1:0.2) at -50 °C, the 
glycosylation gave the orthoester in 88% yield (Table 4, Entry 2). The glycosylation with 
more reactive benzylated acceptor 71 gave a 1:1 mixture of α and β disaccharide 76 and 77 
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(Table 4, Entry 3). The glycosylation with the acceptor 4-SH-glucopyranoside 72 afforded 
mainly α-disaccharide 78 in 53% and minor β-disaccharide 79 was isolated in only 1.5% yield 
(Table 4, Entry 4). The glycosylation with the acceptor 4-selenol-glucopyranoside 73 gave α-
disaccharide 80 in 46% and β-disaccharide 81 in 11% yield (Table 4, Entry 5).  
Table 4. Glycosylation reaction of 5-thio-glucopyranosyl trichloroacetimidate  
a Donor: Acceptor: TESOTf 
 
2.00 Synthesis of 3,5-dithio-glucopyranose 
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Figure 10. Retrosynthetic analysis of oligo-3,5-dithio-β-D-glucopyranoside. 
      At first, we planned to synthesize the oligo-3,5-dithio-β-D-glucopyranoside by base 
promoted S-glycosylation between the acceptor 3,5-dithioglucopyranoside with free 3-SH and 
3,5-dithio-glucopyranosyl bromide as the donor (Figure 10). According to Whistler et al,71 5-
thio-glucopyranose can be prepared from acetolysis of 5-thio-glucofuranose. Therefore, we 
decided to synthesize 3,5-dithio-1,2-O-isopropylidene-glucofuranose as the starting material. 
The proposed synthesis started from 1,2-O-isopropylidene-5,6-didexoy-5,6-epithio-α-D-
allofuranose, which can be prepared in large scale from 1,2;5,6-O-diisopropylidene-α-D-
glucofuranose.72 S-acetyl group could be introduced at C-3 via nucleophlic substitution of 3-
O-trifluoromethanesulfonyl of compound 1,2-O-isopropylidene-5,6-didexoy-5,6-epithio-α-D-
allofuranose to give 3-S-acetyl-1,2-O-isopropylidene-5,6-dideoxy-5,6-dithio-α-D-
glucofuranose. Finally, after ring opening of episulfide by acetate, the acidic acetolysis would 
give the 3,5-dithio-glucopyranose (Scheme 15).  
2.10 Synthesis of 3,5-dithio-α-D-glucofuranose  
2.11 Synthesis of 3,5-dithio-α-D-glucofuranose by nucleophilic substitution on 3-O-
trifluoromethanesulfonyl group of 1,2-O-isopropylidene-5,6-dideoxy-5,6-epithio-α-L-
talofuranose 
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Scheme 15. Proposed synthesis of 3,5-dithio-glucopyranose 
      For the shorter synthetic route, we decided to synthesize 1,2-O-isopropylidene-5,6-
dideoxy-5,6-epithio-β-L-talofuranose 87 as a practice. Starting from 1,2;5,6-O-
diisopropylidene-α-D-glucofuranose 82. The 5,6-O-isopropylidene group was selectively 
removed by acidic hydrolysis and the 6-OH was selectively tosylated to give 6-O-p-
toluenesulfonyl-1,2-O-isopropylidene-glucofuranose in 48% yield. Subsequent deprotonation 
by sodium hydride initiated intramolecular substitution generated the 5,6-anhydro-1,2-O-
isopropylidene-α-D-glucofuranose 85 in 61% yield. The 5,6-epoxide of compound 85 was 
converted to the 5,6-epithio compound 86 by treatment with thiourea. Conversion of the 3-
hydroxyl group by Dess-Martin oxidation and sodium borohydride reduction gave 1,2-O-
isopropylidene-5,6-epithio-α-L-talofuranose 88 in 95% yield.  
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Scheme 16. Attempted synthesis of 3,5-dithio-glucofuranose from compound 87  
      With the compound 87 in hand, we tried to perform a nucleophilic substitution the 
triflate intermediate. Unexpectedly, the reaction afforded the rearrangement product 88 
(Scheme 16). The possible mechanism for the formation of compound 88 is the intramolecular 
nucleophilic replacement generated the episulfonium intermediate, which was substituted by 
the thioacetate at C-6 to give the rearrangement product. (Figure 11). 
 
Figure 11. Proposed mechanism for rearrangement product 88 formation. 
2.12 Synthesis of 3,5-dithio-glucofuranose by epoxide-episulfide transformation of 3-S-
acetyl-1, 2-O-isopropylidene-5, 6-anhydro-α-D-glucofuranose. 
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Scheme 17. Proposed synthesis of 3,5-dithio-glucofuranose by epoxide-episulfide 
transformation 
      The first rearrangement product 88 taught us a lesson about the good nucleophilicity of 
epislfide sulfur. To avoid intramolecular nucleophilic substitution, in another synthetic route, 
we decided to install the first thioacetate at C-3 before the second thioacetate was introduced 
at C-5 (Scheme 17).  
 
Scheme 18. The attempted epoxide formation of compound 92. 
      The synthesis started from 1,2;5,6-di-O-isopropylidene-α-D-glucofuranose. After 
Dess-Martin oxidation and sodium borohydride reduction, the 3-OH underwent inversion to 
give 1,2;5,6-di-O-isopropylidene-α-D-allofuranose 89 in 80% yield. 3-OH of compound 89 
was triflated followed by thioacetate displacement to give 3-S-acetyl-1,2;5,6-di-O-
isopropylidene-α-D-glucofuranose 90 in 84% yield. After the 5,6-isopropylidene group was 
selectively removed with 50% acetic acid, 6-OH was tosylated to give compound 92 in 67% 
yield. When we were treating compound 92 with DBU to prepare 5,6-epoxide, the 
rearrangement product 93 was generated (Scheme 18). The structure was confirmed by 
comparing the spectral data with that of the known compound.73 The possible mechanism is 
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that the acetyl migrated from S-acetyl to the neighboring hydroxyl and the thiolate cyclized to 
give the rearrangment product 93 (Figure 12). 
 
Figure 12. Proposed mechanism for the rearrangement product 93 formation 
2.13 Attempted synthesis of 3,5-dithio-glucofuranose by nucleophilic substitution of the 
trifluoromethanesulfonyl group of 3-O-trifluoromethanesulfonyl-1,2-O-isopropylidene-
5,6-anhydro-α-D-allofuranose 
 
Scheme 19. Proposed synthesis of compound 98 by nucleophilic substitution of 3-O-
trifluoromethanesulfonyl group of compound 97. 
      To avoid the rearrangement, we proposed a new synthetic route in which the thioacetate 
was introduced after the epoxide formation (Scheme 19). We started the synthesis from 
1,2;5,6-di-O-isopropylidene-α-D-allofuranose. After acetylation of the 3-OH and selectively 
acidic hydrolysis of 5,6-O-isopropylidene, we prepared compound 94 in 95% yield. Primary 
alcohol benzoylationg and secondary alcohol sulfonylation gave the desired product 95 in 67% 
yield. After treatment with sodium methoxide, the epoxide formation afforded the 5,6-anhydro-
1,2-O-isopropylidene-α-D-glucofuranose 96 in 49% yield. After the 3-OH was converted to 
the triflate, thioacetate was introduced by slowly adding thioacetate / DMF solution at 0°C to 
give the desired product 3-S-acetyl-5,6-anhydro-1,2-O-isopropylidene-α-D-glucofuranose 98 
in 67% yield. When we performed the epoxide episulfide transformation on compound 98, the 
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reaction gave complex mixtures from which no anticipated product was identified (Scheme 
20).  
 
Scheme 20. The attempted epoxide episulfide transformation of compound 98 
      We installed the S-pivalyl group to prevent the transesterification of the S-acetyl group. 
The S-pivalyl group was installed by a SN2 substitution of triflate by potassium S-pivalate to 
give 3-S-pivalyl-1,2-O-isopropylidene-5,6-anhydro-α-D-glucofuranose 99 in 66% yield. When 
we performed the epoxide-episulfide transformation of the compound 99, the reaction gave the 
product together with inseparable rearrangement prodcut. This result indicated that the S-
pivalyl was not able to completely prevent transesterification (Scheme 21). 
 
Scheme 21. The attempted epoxide episulfide transformation of compound 99 
2.2 Synthesis of the 3,5-dithio-glucopyranose by nucleophilic substitution of the C-3 
triflate of 5-thio-allopyranose 
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Figure 13. Proposed synthesis of the 3,5-dithio-glucopyranose by nucleophilic substitution of 
the C-3 triflate of 5-thio-pyranose 
      We decided to synthesize the 5-thio-allopyranose with an axial triflate at C-3 to install 
the thioacetate (Figure 13). The synthesis started from 1,2;5,6-di-O-isopropylidene-α-D-
allofuranose. The installation of (2-naphthyl)methyl protecting group at 3-OH gave the product 
100 in 91% yield. After acidic hydrolysis of the 5,6-O-isopropylidene group, the primary 
hydroxyl was benzoylated and secondary hydroxyl was mesylated to give the product 102 in 
70% yield. Treatment with sodium methoxide in methanol, neutralization with Amberlyst IR-
120 resin, and subsequent heating with thiourea afforded the 5,6-dideoxy-5,6-epithio product 
103 in 70% yield. Compound 103 was refluxed with potassium acetate in the mixture of acetic 
anhydride and acetic acid to give the ring opening product 104 in 56% yield. With compound 
104, treatment with 60% acqueous trifluoroacetic acid gave a mixture of deprotection products 
including small amount of cyclized product. We followed a two steps protocol of Driguez.74 
First, compound 103 was refluxed in 50% aqueous acetic acid to remove the 1,2-O-
isopropylidene group. Then, the hemiacetal intermediate was treated with sodium methoxide 
and cyclized to give 3-O-(2-naphthyl)methyl-5-thio-α,β-D-allopyranose. The crude mixture 
was subjected to acetylation to give the desired product 105 in 45% yield (Scheme 22).  
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Scheme 22. Synthesis of compound 105. 
      With the compound 105, Zemplén deacetylation follwed by 4,6-O-benzylidene 
protection and acetylation give the 4,6-O-benzylidene protected product 106 in 46% yield. 
Removal of the 3-ONAP protecting group gave the product 107 as an anomeric mixture (α: β 
= 1: 3) (Scheme 23).   
 
Scheme 23. The 4,6-O-benzylidene protection of compound 105 and selective deprotection of 
the NAP group. 
      With compound 107, the installation of triflate group at C-3 followed by SN2 
substitution of the triflate using potassium thioacetate provided 3,5-dithio-glucopyranose 
product 108 in 66% yield (Scheme 24). Reaction of compound 108 with 33% hydrogen 
bromide in acetic acid gave the rearrangement product 109 in 39% (Scheme 24). 
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Scheme 24. The bromination reaction of compound 108 
      Alternatively, we decided to use acetyl protecting group to proceed the synthesis. 
Oxidative deprotection of the 3-ONAP group of 105 afforded the product 110 as anomeric 
mixture (α: β = 1: 1.3). The axial 3-OH of compound 110 was triflated and substituted by 
thioacetate anion to give the acetyl protected 3,5-dithio-glucopyranose derivative 111 in 55% 
yield. The bromination reaction provided the desired glucopyranosyl bromide 112 as an 
anomeric mixture (α: β = 1:1) in 76% yield (Scheme 25).  
 
Scheme 25. Preparation of 3,5-dithio-glucopyranosyl bromide. 
3.00 S-Glycosylation study 
3.10 Base promoted SN2 substitution of anomeric bromide by sodium ethanethiolate  
      With the 3,5-dithio-glucosyl bromide 112 in hand, we performed the SN2 substitution 
of anomeric bromide by ethane thiolate in DMF. The reaction did not give the desired product. 
(Scheme 26).  
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Scheme 26. Attempted sodium ethane thiolate substitution of 5-thio-glucopyranosyl bromide 
3.20 Acid catalyzed S-glycosylation of 3,5-dithio-glucopyranosyl trichloroacetimidate 
      Alternatively, we decided to try the acid catalyzed S-glycosylation to build up the thio-
linked disaccharide. Selective S-acetyl deprotection was performed to prepare the 
glycosylation acceptor. However, when the compound 111 was treated with hydrazine 
monohydrate, the reaction gave both 3-S-acetyl deprotection product 113 and anomeric O-
acetyl deprotection product 114 in 13% and 45% respectively. To improve the yield, the 
sodium ethanethiolate was added in DMF at -40 °C and 3-thioacetate was selectively removed 
to give 3-S-acetyl deprotected product 113 in 59% yield75 (Scheme 27).  
 
Scheme 27. Preparation of compound 113 as S-glycosylation acceptor 
      To avoid 3-S-acetyl deprotection, a two steps protocol was applied to prepare the 
glycosylation donor. First, the anomeric bromide of 112 was hydrolyzed in the presence of 
TBAI to give compound 115 in 62% yield. With compound 115, the anomeric hydroxyl was 
treated with trichloroacetonitrile and catalytic amount of DBU to give the glucopyranosyl 
trichloroacetimidate 116 in 75% yield. With both donor and acceptor in hand, we performed 
the TMSOTf promoted glycosylation at -78 °C and it was not successful (Scheme 28).  
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Scheme 28. Synthesis of donor 116 and attempted TMSOTf catalyzed S-glycosylation 
4.00 Oligo-(3,5-dithio-β-D-glucopyranosides) synthesis 
4.10 Synthesis of 3-O-trifluoromethanesulfonyl-1,2-O-isopropylidene-5-S,6-O-
isopropylidene-5-thio-α-D-allofuranose and its application in the disaccharide synthesis 
 
Scheme 29. Synthesis of compound 119 
      Based on Ferrières’s synthesis57 and Hindsgaul’s work76 to synthesize thio-linked 
oligosaccharide, we designed the 3-O-trifluoromethanesulfonyl-1,2-O-isopropylidene-5-S,6-
O-isopropylidene-5-thio-α-D-allofuranose 119 as the key building block for the oligomer 
synthesis. Compound 105 was deacetylated and stirred with p-toluenesulfonic acid in 
anhydrous acetone to give the diisopropylidene glucofuranose derivative 117 in 73% yield.77 
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The 3-O-(2-naphthyl)methyl protecting group was removed by DDQ and the 3-OH was 
converted to the triflate to give the building block 119 in 80% yield (Scheme 29).  
 
Scheme 30. The disaccharide synthesis by coupling reaction.  
With the compound 119, we performed the coupling reaction with the glucopyranosyl 
thioacetate 120 to give the disaccharide mimetic 121 in 46% yield. After the silica gel 
chromatography, extra triflate compound 119 were recycled without any rearrangement or 
elimination reaction. This result demonstrated that the triflate compound 119 can serve as the 
building block for oligomerization (Scheme 30). 
4.20 Large-scale synthesis of penta-O-acetyl-5-thio-α,β-D-glucopyranose 
 
Scheme 31.The large-scale synthesis of penta-O-acetyl-5-thio-a,β-D-glucopyranose 
The success in thiol-triflate coupling reaction helps us to proceed the oligomer synthesis. 
The linear synthetic route requires a large amount of monosaccharide 5-thio-glucopyranose as 
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starting material. We followed the synthetic route of Whistler78 to scale up 5-thio-
glucopyranose synthesis. 3-O-acetyl-1,2-O-isopropylidene-α-D-glucofuranose 122 was 
synthesized after acetylation and the selective isopropylidene deprotection of 5,6-O-
isopropylidene.79 The primary alcohol was selectively benzoylated followed by sulfonylation 
of secondary alcohol to give fully functionalized glucofuranose derivative 123 in 83% yield. 
Treatment of sodium methoxide and neutralization by Amberlyst IR 120 resin gave 1,2-O-
isopropylidene-5,6-anhydro-α-D-glucofuranose, which was converted to 1,2-O-
isopropylidene-5,6-didexoy-5,6-epithio-α-D-glucofuranose 124 in 65% yield. The ring 
opening of episulfide by potassium acetate gave the 5-S-acetyl-3,6-di-O-acetyl-1,2-O-
isopropylidene-α-D-glucofuranose 125 in 42% yield. Adapting the protocol of Driguez74, the 
5-thio-glucofuranose was rearranged to 5-thio-glucopyranose penta-acetate 126 in 60% yield 
(Scheme 31). 
      With large amount of penta-O-acetyl-5-thio-α,β-D-glucopyranose in hand. We 
synthesized the building block 1-S-Acetyl-2,3,4,6-tetra-O-acetyl-1,5-dithio-β-D-
glucopyranose 128. The bromination of penta-O-acetyl-5-thio-glucopyranose gave a mixture 
of anomeric bromide 127, which was substituted by potassium thioacetate to give 1-S-acetyl-
2,3,4,6-tetra-O-acetyl-1,5-dithio-β-D-glucopyranose 128 in 46% yield (Scheme 32).  
 
Scheme 32. The Large-scale synthesis of compound 128 
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      Another building block 119 was also synthesized in gram scale from penta-O-acetyl-5-
thio-glucopyranose. First, Zemplén deacetylation of the penta-O-acetyl-5-thio-a,β-D-
glucopyranose gave a crude preparation of 5-thio-glucose which was stirred in anhydrous 
acetone with p-toluenesulfonic acid to give the 1,2-O-5-S,6-O-di-isopropylidene glucofuranose 
129 in 73% yield77. Swern Oxidation was performed on substrate 129 to give a ketone 
intermediate which was immediately subjected to sodium borohydride reduction to give the 
1,2-O-5-S,6-O-di-isopropylidene-5-thio-α-D-allofuranose 118 in 57% yield. Finally, the 3-OH 
was converted to triflate to give the building block 119 in 85% yield (Scheme 33). 
 
Scheme 33 The Large-scale synthesis of 3-O-trifluoromethanesulfonyl-1,2-O-isopropylidene-
5-S,6-O-isopropylidene-5-thio-α-D-allofuranose 
4.30 Synthesis of the disaccharide mimetic 
 
Scheme 34. Synthesis of disaccharide mimetic 133 
      With grams of the building blocks 128 and 119. The first coupling reaction was 
performed under Von Itzstein condition to give the disaccharide intermediate 130 in 86% yield.  
The deprotection was based on a 3 steps procedure. First, Zemplén deacetylation gave free-OH 
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disaccharide intermediate 131, which was soluble in water. In the aqueous solution of 
intermediate 131 was added DOWEX-50 and heat up to 90 oC to remove the isopropylidene 
groups. In the acidic hydrolysis procedure, the furanose ring opened to give the open chain 
form with the protonated aldehyde. Cyclization of the aldehyde intermediate gave the 
pyranose-form product as the thermodynamic product (Figure 14). The crude mixture was 
acetylated to give the per-O-acetyl disaccharide 132 in 93% yield. Finally, Zemplén 
deacetylation and Sephadex G-25 gel purification gave the free-OH disaccharide mimetic 133 
in 95% yield (Scheme 34).  
 
Figure 14. The rearrangement from compound 131 to compound 133 
4.40 Synthesis of the trisaccharide and tetrasaccharide mimetic 
      The elongation of disaccharide was based on a 3 steps procedure. First, bromination 
reaction of the anomeric carbon gave the anomeric α-bromide at the reducing end. Second, the 
anomeric bromide was substituted by potassium thioacetate in a SN2 fashion to give the 
anomeric thioacetate with β-configuration. Finally, under Von Itzstein condition, the terminal 
β-thioacetate was deprotected and substituted the triflate of compound 119 to give the coupling 
product. The synthesis started from 2,3,4,6-tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-
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substituted by thioacetate anion to give the glucopyranosyl thioacetate intermediate 135 in 89% 
yield. Under Von Itzstein condition, compound 135 was coupled with triflate 119 to give the 
trisaccharide intermediate 136 in 64% yield. Adapting the same deprotection procedure applied 
in disaccharide synthesis, compound 136 was deprotected and purified by Sephadex G-25 gel 
chromatography to give the trisaccharide mimetic 139 (Scheme 35).  
 
Scheme 35. Synthesis of the trisaccharide mimetic 139 
      The synthesis of tetrasaccharide started from per-O-acetyl trisaccharide 138. 
Bromination reaction gave the glucopyranosyl bromide intermediate 140 in 43% yield, the 
bromide was substituted by thioacetate anion to give the glucopyranosyl thioacetate 
intermediate 141 in 90% yield. The compound 141 was coupled with triflate 119 to give the 
tetrasaccharide intermediate 142 in 46% yield. Application of the deprotection procedure to 
the tetrasaccharide intermediate 142 gave the tetrasaccharide mimetic 144 in 85% yield 
(Scheme 36). 
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Scheme 36. Synthesis of the tetrasaccharide mimetic 144 
5.00 Biological evaluation of the oligo-(3,5-dithio-β-D-glucopyranosides) 
      To evaluate the binding affinity of the oligo-(3,5-dithio-β-D-glucopyranosides) to CR3 
and Dectin-1, the Vetvicka laboratory tested the mimetics’ ability to inhibit anti-CR3 and anti-
Dectin-1 fluorescein isothiocyanate (FITC) conjugated antibody staining of human neutrophils 
and mouse macrophages. In terms of CR3 binding affinity, incubation of a 0.1μg / ml solution 
of β-(1→3)-dimer mimetic 133 caused 20% decreases in inhibition of staining human 
neutrophils and β-(1→3)-trimer mimetic 139 caused 37% decreases in inhibition of staining 
human neutrophils, while the β-(1→3)-tetramer mimetic 144 caused 21% decreases (Table 5). 
In terms of Dectin-1 binding affinity, incubation of a 0.1μg/ml solution of β-(1→3)-dimer 
mimetic 133 caused 31% decreases in inhibition of staining human neutrophils and β-(1→3)-
trimer mimetic 139 caused 42% decreases in inhibition of staining human neutrophils, while 
the β-(1→3)-tetramer mimetic 144 caused 33% decreases (Table 5).  
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Table 5. Percentage inhibition of anti-CR3 and anti-Dectin-1-FITC antibody staining of 
neutrophils, macrophages by 0.1μg/mL substrate. a Mean ± SD 
                                                                       
 
Compound 
 
Oligomer 
NO. 
% inhibition of anti-
CR3-FITC staining   
human neutrophilsa 
% inhibition of anti-
dectin-1-FITC 
staining of mouse 
neutrophilsa 
133 Dimer 20.2 ± 1.7 30.9 ± 3.4 
139 Trimer 37.3 ± 3.2 42.2 ± 3.8 
144 Tetramer 21.5 ± 1.4 33.1 ± 2.9 
                                                                        
      Oligo-(3,5-dithio-β-D-glucopyranosides) 133, 139, 144 (10 μg / mL) were also tested 
for their ability to stimulate phagocytosis of human macrophage-like RAW 264 cells.55 
Commercial available β-glucan Glucan #300 were used as reference (Table 6). The result 
indicates that the β-(1→3)-trimer mimetic 139 could stimulate 16% of phagocytosis, which is 
more effective than the β-(1→3)-dimer 133 and β-(1→3) tetramer mimetic 144. It is notable 
that the level of phagocytosis stimulated by the β-(1→3)-trimer mimetic 139 was about 50% 
of that induced by Glucan #300.  
Table 6. Percentage stimulation of phagocytosis. a Mean ± SD 
                                                                          
Compound Oligomer NO. % stimulation of phagocytosis (RAW 264 
macrophages, 10μg / mL, 24h) a 
133 Dimer 8.7 ± 0.7 
139 Timer 16.3 ± 0.9 
144 Tetramer 6.9 ± 0.3 
Glucan #300 Polymer 37.5 ± 2.5 
PBS  2.1 ± 0.2 
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      Oligo-(3,5-dithio-β-D-glucopyranosides) 133, 139, 144 (10 μg / mL) were also tested 
for their ability to stimulate pinocytosis of human macrophage-like RAW 264 cells.55 
Commercial available Glucan #300 was used as reference. The result indicates that the β-
(1→3)-trimer mimetic 139 could stimulate 13% of pinocytosis, which is more effective than 
the β-(1→3)-dimer mimetic 144 and β-(1→3)-tetramer mimetic 145 (Table 7).  
Table 7. Percentage stimulation of pinocytosis. a Mean ± SD* 
                                                                          
Compound Oligomer NO. % stimulation of pinoocytosis (RAW 264 
macrophages, 10μg / mL, 24h) a 
133 Dimer 7.77 ± 1.61 
139 Timer 12.8 ± 1.72 
144 Tetramer 3.37 ± 0.36 
Glucan #300 Polymer 38.9 ± 2.81 
PBS  1.77 ± 0.11 
                                                                          
*Pinocytosis was assayed by spectrophotometric measurement of neutral red dye accumulation 
by mouse macrophages after 2 hr incubation with 40 μg/ml of neutral red. 
6.00 Conclusion 
      As already demonstrated with the di- and trimeric hydroxylamines 22 and 25,54 the 
present study demonstrates that small molecule mimetics of β-(1→3)-glucans can be designed 
that display significant activity in the inhibition of staining of human neutrophils and mouse 
macrophages by fluorescent anti-CR3 and anti-Dectin-1 antibodies suggestive of binding to 
the carbohydrate binding domains of the respective proteins. The affinity for the carbohydrate 
binding domains of CR3 and Dectin-1 is reflected in the stimulation of phagocytosis and of 
pinocytosis by compounds 133, 139 and 144. Unexpectedly, the trimer 139 is more active than 
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either the dimer 133 or the tetramer 144 in each of the three assays conducted suggesting that, 
at least for the present series of glucan mimetics, there is little to be gained by preparing higher 
oligomers.  This maximization of activity in the trimer 144 might be accounted for by a 
tradeoff between the greater affinity for the CR3 and Dectin-1 carbohydrate binding sites 
arising from the presence of the multiple thioethers on the positive side, and the accumulation 
of multiple long C-S bonds eventually causing a mismatch with the binding site on the negative 
side. 
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CHAPTER 3: DEVELOPMENT OF A MICROWAVE CLEAVABLE PROTECTING 
GROUP AND ITS APPLICATION IN GLYCOSYLATION. 
1.00 Introduction 
      Protecting groups are integral for advancing the art of organic synthesis.80-81 They are 
employed in the construction of complex natural products, oligosaccharides, polyketides, RNA, 
and peptides. Despite reports on protecting group-free complex molecule synthesis.82 In 
organic synthesis, especially carbohydrate synthesis, it is necessary to manipulate different 
functional groups, which lead to the concept of orthogonal protecting groups. The benzyl 
protecting group, as well as modified benzyl groups, have been significantly employed in 
hydroxyl group protection. The electronic tuning of the benzyl group has generated different 
orthogonal protecting groups: a) Chemical cleavable protecting groups; b) Photocleavable 
protecting groups; c) Enzyme cleavable protecting groups. We have expanded this boundary 
to a new type of protecting group: Microwave cleavable protecting groups.   
1.10 Chemical cleavable benzyl protecting groups 
1.11 Benzyl protecting groups cleaved by hydrogenolysis 
Benzyl groups are most frequently used for hydroxyl group protection. They are stable 
under acidic and basic conditions, and they are only hardly cleavable under mild oxidizing 
agents (Dess-Martin Reagent, etc) or metal hydrides (Lithium Aluminum Hydride, etc). The 
deprotection method is usually hydrogenolysis in the presence of Palladium catalyst on 
charcoal, this process is mild and compatible with most functional groups.83  
1.12 Benzyl based protecting groups cleaved by oxidation 
      p-Methoxy benzyl (PMB) as well as 3,4-dimethoxybenzyl (DMB) ethers were 
developed by Yonemitsu group.84 They are more labile under acidic conditions than benzyl 
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ether. However, they undergo oxidative cleavage, a process where single electron transfer (SET) 
to 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), generating an oxonium ion which can 
be captured by water. This characteristic provides an orthogonal set which helps to selectively 
remove PMB ethers in the presence of benzyl ether.  
1.20 Microwave 
Mirowave is a form of electromagnetic energy with wavelength range from one meter 
to one millimeter. The development of microwave technology was initiated by World War II 
as the RADAR devices. Accidentally, Percy LeBaron Spencer of the Raytheon Company 
discovered that microwave energy could heat up food. This discovery gave birth to commercial 
microwave oven in the 1950s. Microwave was applied in Organic synthesis in 1980s, the first 
two papers on microwave-enhanced organic chemistry were published and many in 1986. 
Organic chemists have since discovered the benefits of using microwave energy to drive 
synthetic reactions.85-86 Microwave heating is much more quickly than conductive heating 
since heat doesn’t need to pass through the walls of vessel to heat up the reactant. Microwave 
heating has been proved to be significantly beneficial in accelerating many conventional heated 
reactions. The ease of manipulation, milder reaction conditions and formation of cleaner 
products are the benefits come with improved reaction rates.87   
1.30 Microwave cleavable benzyl-based protecting groups 
1.31 Microwave cleavage of 4-O-siloxyl benzyl ether  
      The Crich lab developed a microwave assisted cleavage of 4-(tert-Butyldiphenylsiloxy)-
3-fluorobenzyl group. 88 The deprotection was performed with TBAF under microwave 
condition. Orthogonality was tested with PMB ether and it was proved that the 4-(tert-
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Butyldiphenylsiloxy)-3-fluorobenzyl ether was deprotected in the presence of PMB ether 
(Scheme 37).  
 
Scheme 37. Microwave cleavage of 4-(tert-Butyldiphenylsiloxy)-3-fluorobenzyl group 
1.32 Microwave cleavage of PDMAB protecting group  
      Andreana group discovered PDMAB protecting group in a microwave reaction of 
compound 148. Under the cleavage of p-N,N-dimethylamine benzyl group in 98% yield. This 
discovery led us to look for appropriate protection reagents to help to extent PDMAB group 
into organic synthesis (Scheme 38).  
 
Scheme 38. Microwave cleavage of PDMAB group of compound 148 
2.00 p-N,N-Dimethylamino benzyl group protection  
2.10 Installation of PDMAB group by nucleophilic substitution of PDMAB chloride or 
PDMAB tosylate  
 
Figure 15. Installation of PDMAB group by nucleophilic substitution 
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      In benzyl ether synthesis, the most common method is the alkylation of alkoxides with 
benzyl bromide or chloride. We wanted to apply this method to PDMAB group installation 
(Figure 15). With the commercially available p-N,N-dimethylamino benzaldehyde, the 
reduction with sodium borohydride gave p-N,N-dimethylamino benzyl alcohol 150 in 85% 
yield. Tosylation of the PDMAB alcohol in DMF gave the 4,4’-methylenebis-(N,N-
dimethylaniline) 151 as the major product (Scheme 39).  
 
Scheme 39. Attempted synthesis of PDMAB tosylate 
      The PDMAB aocohol was refluxed in concentrated hydrogen chloride at 100 oC 
overnight to give the p-N,N-dimethylamino benzyl chloride hydrochloride salt 152 in 96% 
yield. When applying this reagent in hydroxyl group protection, no protection product was 
isolated and the major product was 4,4’-methylenebis-(N,N-dimethylaniline) 151. This result 
indicates that p-N,N-dimethylamino benzyl chloride hydrochloride salt decompose under basic 
condition (Scheme 40). 
 
Scheme 40. Synthesis of PDMAB chloride hydrochloride and attempted PDMAB protection 
2.20 Buchwald amination of 4-halobenzyl ether. 
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Figure 16. Installation of PDMAB protecting group by Buchwald amination of 4-halobenzyl 
ether 
      Obadiah et al89 reported that p-N,N-dimethylamino benzyl protecting group could be 
installed by Buchwald amination of 4-halobenzyl ether. We successfully installed PEMAB 
group on the 1,2;5,6-di-O-isopropylidene-α-D-glucofuranose by applying this protocol. First, 
the 3-OH of compound 82 was protected with 4-chlorobenzyl group to give 3-O-(4-
Chlorobenzyl)-1,2;5,6-di-O-isopropylidene-α-D-glucofuranose 153 in 78% yield. Buchwald 
amination was performed with compound 153 using diethyl amine to give PEMAB protected 
1,2;5,6-di-O-isopropylidene-α-D-glucofuranose 154. We tested the deprotection of PEMAB 
group under microwave condition and the PEMAB group was successfully cleaved under 
microwave irradiation to give compound 82 in 53% yield together with the p-N,N-diethylamino 
benzyl methyl ether 159 as the byproduct (Scheme 41).  
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Scheme 41. The installation of p-N,N-diethylamino benzyl ether and microwave deprotection 
      Out of curiosity, we also tested microwave deprotection of the ortho-N,N-
dimethylamino benzyl group. First, the 3-OH of compound 82 was protected with ortho-N,N-
dimethylamino benzyl group using ortho-N,N-dimethylamino benzyl chloride. The reaction 
gave the desired product 158 in 55% yield. When compound 158 was subjected to microwave 
irradiation in methanol, the ortho-N,N-dimethylamino benzyl group was not cleaved (Scheme 
42).  
 
Scheme 42. Installation of ortho-N,N-dimethylamino benzyl ether and attempted microwave 
deprotection 
2.30 Application of PEMAB group in glycosylation 
      The task of manipulating different hydroxyl groups becomes particularly important in 
oligosaccharide synthesis. To accomplish this task, orthogonal protection and deprotection is 
required in the complex molecule synthesis. Different protecting groups are employed, for 
example, 4-O-methoxy benzyl ethers, which is labile under oxidative condition and acidic 
condition, can be selectively cleaved in the presence of benzyl groups. More importantly, the 
compatibility of protecting groups with the glycosylation reaction will help to diversify the 
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oligosaccharide synthesis. To test the compatibility of PEMAB group in glycosylation, we 
synthesized the phenyl 4-O-(p-N,N-diethylamino benzyl)-2,3-O-isopropylidene-1-thio-β-L-
rhamnopyranoside 161 and it was subjected to NIS / TMSOTf activated glycosylation. The 
synthesis started from Phenyl 2,3-O-isopropylidene-1-thio-β-L-rhamnopyranoside 161, the 4-
OH was protected by 4-bromobenzyl ether give compound Phenyl 4-O-(4-bromobenzyl)-2,3-
O-isopropylidene-1-thio-β-L-rhamnopyranoside 162 in 85% yield. The Buchwald amination 
converted the 4-bromobenzyl ether protected rhamnose 162 into p-N,N-diethylamino benzyl 
protected rhamnose 163 in 82% yield. With glycosylation donor 163 in hand, the glycosylation 
with methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside was undertaken. The reaction was 
activated by NIS / TMSOTf  at -78 oC and stirred at -78 oC for 12 h to give the glycosylation 
product 162 in 22% yield (Scheme 43). With glycosylation product 162, we performed the 
deprotection under microwave irradiation. The PEMAB group was cleaved to give the product 
163 in 73% yield (Scheme 43). 
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Scheme 43. Glycosylation with PEMAB protected donor 161 and deprotection of PEMAB 
group after glycosylation reaction 
3.00 Conclusion 
      In conclusion, other than traditional orthogonal protecting groups: the chemical labile, 
photo labile and enzymatic labile protecting groups. A new type of protecting group: 
microwave labile protecting group, has been developed.) To the best of oue knowledge, this is 
the first example where microwave irradiation has been used to deprotect benzyl ether 
protecting groups. It was convinced that the PEMAB group is compatible with glycosylation 
conditions. The PEMAB group can be selectively deprotected in the presence of benzyl ether, 
isopropilydene, ester as well as benzylidene acetals under microwave irradiation at neutral 
conditions. As for the protection, the effective procedure requires a two steps synthesis: 
 59 
installation of p-halo-benzyl ether and Buchwald amination. The one step protection is limited 
by the unstability of PEMAB chloride or tosylate.  
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CHAPTER 4: EXPERIMENTAL SECTION 
General information 
      All reagents and solvents were purchased from commercial suppliers and were used 
without further purification unless otherwise stated. All reactions were performed under Argon 
atmosphere unless otherwise stated. Reactions were monitored by analytical thin-layer 
chromatography with pre-coated glass backed plates (w/UV 254) and visualized by UV 
absorption (254 nm) or by staining with a 5% solution of H2SO4 in MeOH or ceric ammonium 
molybdate solution (4.0 g ceric sulfate; 10 g ammonium molybdate; 40 mL H2SO4; 360 mL 
H2O) followed by heating. Optical rotations were measured with an Autopol III polarimeter 
(Rudolph Research Analytical, Hackettstown, NJ) in the solvent specified at 589 nm at 23 °C, 
the path length is 10 cm. 1H, 13C, HSQC, HMBC, COSY, TOCSY NMR spectra were recorded 
with Agilent 600 MHz and Varian 400 MHz instruments. High resolution mass spectra were 
recorded with a Walters LC/ MS with an electrospray source coupled to a time-of-flight mass 
analyzer. Melting points were recorded with a Barnstead International electrothermal melting 
point apparatus. 
General Procedure A: Coupling Reactions 
      To a solution of 1-S-Acetyl-5-thio-β-D-glucopyranose (1.0 eq) and 1,2-O-5-S,6-O-di-
isopropylidene-5-thio-α-D-allofuranose (1.1 eq) in DMF (1.0 M) was added diethylamine (2.5 
eq) dropwise at 0 °C. The reaction mixture was stirred at room temperature until completion. 
The reaction mixture was diluted with ethyl acetate and washed with water, brine, dried over 
MgSO4 and concentrated in vacuo. The residue was purified by silica gel chromatography.  
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General Procedure B: Deacetylation  
At 0 °C, sodium methoxide (0.2 eq) was added to the substrate (1.0 eq) in anhydrous methanol 
(0.1M) and stirred until the completion of the reaction (observed by mass spectrometry). 
Amberlyst IR120 resin was added to neutralize the reaction. When the pH was neutral 
(monitored by pH paper), the resin was filtered off and the solution was concentrated in vacuo. 
Furanosyl systems were subjected to acidic hydrolysis according to general procedure C, and 
the pyranose forms were purified by Sephadex G-25 gel eluting with water. 
General procedure C: Hydrolysis and Acetylation 
      The substrate (1.0 eq) was dissolved in deionized water (0.05 M). DOWEX-50WX2 
hydrogen form resin (400 mg per 100 mg substrate) was added to the reaction. The reaction 
mixture was stirred at 90 °C until the completion of the reaction (monitored by mass 
spectrometry). The resin was filtered off and the solution was concentrated in vacuo. The crude 
mixture was dissolved in pyridine (0.5 M) and acetic anhydride (2 eq per OH) 4-
(dimethylamino)-pyridine (0.1 eq) was added, the reaction mixture was stirred at room 
temperature until the completion of reaction (monitored by mass spectrometry). The solution 
was concentrated in vacuo and purified by silica gel chromatography. 
General Procedure D: Bromination 
      To a solution of penta-O-acetyl-5-thio-D-glucopyranose (1.0 eq) in anhydrous DCM 
(0.5 M) was added 33% HBr in acetic acid (7.0 eq) at 0 °C. The reaction mixture was kept at 
5 °C for 12 h. The reaction mixture was diluted by DCM and quenched with ice cold aqueous 
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NaHCO3. The organic layer was washed with water, brine, dried with MgSO4, and 
concentrated in vacuo. The residue was purified by silica gel chromatography. 
General procedure E: Thioacylation  
      At 0 °C, potassium thioacetate (1.5 eq) was added to a solution of penta-O-acetyl-5-
thio-D-glucopyranosyl bromide (1.0 eq) in N,N-dimethyl formamide (1.0 M). The reaction 
mixture was stirred 12 h at room temperature. After completion, the reaction mixture was 
diluted with ethyl acetate and washed by water, brine, and dried with MgSO4. The reaction 
mixture was concentrated in vacuo and purified by silica gel chromatography.  
5,6-Dideoxy-5,6-epithio-1,2-O-isopropylidene-β-L-talofuranose (87) 
      To a solution of compound 86 (100 mg, 0.46 mmol) in 10 mL DCM was added Dess 
Martin reagent (390 mg, 0.92 mmol). The reaction was stirred at room temperature 24h and 
saturated NaS2O3 aqueous solution was added to quench the reaction. The reaction mixture was 
extracted into DCM and washed with NaHCO3 aqueous solution, water, brine and dried over 
MgSO4. The crude mixture was concentrated in vacuo and re-dissolved in 20 mL EtOH. At 
0 °C, sodium borohydride (26 mg, 0.69 mmol) was added into reaction mixture and it was 
stirred at 0 °C for 1h. The reaction was quenched with aqueous NH4Cl and concentrated in 
vacuo to remove EtOH. After the EtOH was removed, the crude mixture was diluted in ethyl 
acetate, the organic layer was separated and washed with water, brine and dried over MgSO4. 
The crude mixture was concentrated in vacuo and purified by silica gel chromatography to give 
product 87 (85 mg, 85%) as a colorless oil. [α]23D = +57.2° (c 0.6, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 5.81 (d, J = 3.9 Hz, 1H, H1), 4.60 (dd, J = 5.2, 3.9 Hz, 1H, H2), 3.91 – 3.79 (m, 1H, 
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H4), 3.58 (dd, J = 8.5, 6.4 Hz, 1H, H3), 3.06 (td, J = 6.5, 5.4 Hz, 1H, H5), 2.54 (dd, J = 6.6, 1.4 
Hz, 1H, H6’), 2.48 (dd, J = 5.4, 1.4 Hz, 1H, H6), 2.43 (d, J = 10.6 Hz, 1H, OH), 1.54 (s, 3H), 
1.36 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 112.9 (O,O-isopropylidene), 103.9 (C1), 83.2 (C2), 
78.7 (C4), 75.8 (C3), 34.4 (C5), 26.6, 26.5 (isopropylidene), 21.1 (C6). HRMS m/z [M+Na]+ 
calcd for C9H14O4SNa 241.0510, found 241.05010 
6-S-Acetyl-3,5-dideoxy-3,5-epithio-1,2-O-isopropylidene-β-L-idofuranose (88) 
      At 0°C, to a solution of compound 87 (107 mg, 0.49 mmol) in pyridine (1.5 mL) was 
added trifluoromethanesulfonic anhydride (0.1 mL, 0.6 mmol). The reaction was stirred at 0 °C 
for 25 min before it was diluted with diethyl ether 20 mL. The reaction mixture was quenched 
with aqueous NaHCO3 and the organic layer was separated and washed with water, brine and 
dried over MgSO4. The reaction mixture was concentrated in vacuo and re-dissolved in 2 mL 
DMF. At room temperature, potassium thioacetate (171 mg, 1.5 mmol) was added to the 
solution. The reaction was stirred at room temperature for 1h before it was diluted in diethyl 
ether 20 mL and washed with water, brine, dried over MgSO4 and concentrated in vacuo. The 
crude mixture was purified on silica gel chromatography with eluent (hexane : ethyl acetate = 
10 : 1) to give product 88 (50 mg, 37%) as a colorless oil. [α]23D = +81.9° (c 0.4, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 6.35 (d, J = 3.4 Hz, 1H, H1), 5.24 (t, J = 5.0 Hz, 1H, H3), 4.63 (d, 
J = 3.4 Hz, 1H, H2), 3.97 (d, J = 5.0 Hz, 1H, H4), 3.91 (td, J = 7.8, 5.0 Hz, 1H, H5), 3.13 (d, J 
= 7.8 Hz, 2H, H6), 2.32 (s, 3H, S-Acetyl), 1.45 (s, 3H), 1.36 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 195.2 (S-Acetyl), 114.3 (Isopropylidene C), 108.7 (C1), 85.9 (C2), 83.4 (C3), 42.6 
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(C5), 42.0 (C4), 30.6 (S-Acetyl), 30.1 (C6), 27.8 (Isopropylidene), 27.3 (Isopropylidene). 
HRMS m/z [M+Na]+ calcd for C11H16O4S2Na 299.0388, found 299.0384. 
3-S-Acetyl-6-O-p-toluenesulfonyl-1,2-O-isopropylidene-α-D-glucofuranose (92). 
      To a solution of 3-S-acetyl-1,2-O-isopropylidene-α-D-glucofuranose in pyridine 1 mL 
was added p-toluenesulfonyl chloride (56 mg, 0.30 mmol). The reaction mixture was kept in 
5 °C for 24 h before it was diluted in 20 mL DCM and quenched with aqueous NaHCO3. The 
organic layer was separated and washed with water, brine and dried over MgSO4. The crude 
mixture was concentrated in vacuo and purified by silica gel chromatography to give product 
92 (85 mg, 67%) as a colorless oil. [α]23D = -2.6° (c 0.4, CHCl3). 1H NMR (400 MHz, CDCl3) 
δ 7.85 – 7.70 (m, 2H), 7.33 (d, J = 8.1 Hz, 2H), 5.72 (d, J = 3.5 Hz, 1H, H1), 4.56 (d, J = 3.5 
Hz, 1H, H2), 4.30 (dd, J = 10.4, 2.2 Hz, 1H, H6), 4.25 (dd, J = 9.1, 3.6 Hz, 1H, H4), 4.17 (d, J 
= 3.5 Hz, 1H, H3), 4.03 (dd, J = 10.4, 7.0 Hz, 1H, H6’), 3.93 (ddd, J = 9.2, 7.0, 2.2 Hz, 1H, H5), 
2.44 (s, 6H), 2.39 (s, 3H), 1.48 (s, 3H), 1.28 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 194.5, 
145.0, 132.5, 129.9, 128.0, 112.4, 104.6 (C1), 85.6 (C2), 77.3 (C4), 71.9 (C6), 68.8 (C5), 50.3 
(C3), 31.0, 26.4, 26.2, 21.7. HRMS m/z [M+Na]+ calcd for C18H24O8S2Na 455.0810, found 
455.0814 
3-O-Acetyl-5-O-methanesulfonyl-6-O-benzoyl-1,2-O-isopropyliene-α-D-allofuranose (96). 
      At 0 °C, to a solution of compound 95 (460 mg, 1.75 mmol) in DCM 18 mLwas added 
pyridine (0.35 mL, 4.38 mmol). At -30 °C, benzoyl chloride (0.22 mL, 1.93 mmol) was added 
into the reaction, after the reaction was stirred at -30 °C for 1h, methanesulfonyl chloride (0.27 
mL, 3.5 mmol) was injected into the reaction mixture. The reaction was stirred at room 
 65 
temperature overnight before aqueous NaHCO3 was added to quench the reaction. The DCM 
layer was separated and washed with water, brine, dried over MgSO4 and concentrated in vacuo. 
The crude mixture was purified by silica gel chromatography to give product 96 (660 mg, 85%) 
as a colorless crystal. m.p. 128 - 130 °C. [α]23D = +73.6° (c 0.5, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 8.06 (dt, J = 7.2, 1.4 Hz, 2H), 7.65 – 7.52 (m, 1H), 7.45 (dd, J = 8.4, 7.1 Hz, 2H), 
5.83 (d, J = 3.3 Hz, 1H), 5.22 (dt, J = 7.5, 3.6 Hz, 1H), 4.97 – 4.80 (m, 2H), 4.65 (dd, J = 12.4, 
3.5 Hz, 1H), 4.41 (ddd, J = 7.8, 6.8, 4.2 Hz, 2H), 3.05 (s, 3H), 2.11 (s, 3H), 1.55 (s, 3H), 1.34 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.0, 165.9, 133.5, 129.8, 129.2, 128.6, 113.6 (O,O-
isopropylidene), 104.1 (C1), 78.1 (C2), 76.0 (C4), 72.4 (C3), 62.6 (C6), 38.8 (OMs), 26.7, 26.6, 
20.6 (OAc). HRMS m/z [M+Na]+ calcd for C19H24O10SNa 467.0988, found 467.0993. 
5,6-Anhydro-1,2-O-isopropylidene-β-L-talofuranose (97) 
      To a solution of comound 96 (288 mg, 0.65 mmol) in 11 mL MeOH was added sodium 
methoxide (12 mg , 0.22 mmol). The reaction mixture was stirred at room temperature for 1h 
before it was neutralized with Amberlyst IR 120. The crude mixture was concentrated and it 
was purified by sílica gel chromatography to give product 97 (64 mg, 49%) as a colorless oil. 
[α]23D = +30.2° (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.77 (d, J = 3.8 Hz, 1H, H1), 
4.55 (dd, J = 5.1, 3.8 Hz, 1H, H2), 3.96 (ddd, J = 10.4, 8.8, 5.1 Hz, 1H, H3), 3.67 (dd, J = 8.8, 
4.3 Hz, 1H, H4), 3.14 (td, J = 4.2, 2.8 Hz, 1H, H5), 2.90 – 2.74 (m, 2H, H6 & H6’), 2.57 (d, J = 
10.4 Hz, 1H, OH), 1.53 (s, 3H), 1.34 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 112.9 (O,O-
isopropylidene), 104.1 (C1), 79.7 (C2), 78.5 (C4), 72.9 (C3), 51.0 (C5), 43.9 (C6), 26.5 (O,O-
isopropylidene). HRMS m/z [2M+Na]+ calcd for C18H28O10Na 427.1580, found 427.1586. 
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3-S-Acetyl-5,6-anydro-1,2-O-isopropylidene-β-L-idofuranose (98). 
      To a solution of compound 97 (74 mg, 0.37 mmol) in DCM 7.5 mL was added pyridine 
(0.12 mL, 1.42 mmol). At 0 °C, trifluoromethanesulfonic anhydride (0.12 mL, 0.71 mmol) was 
added dropwise. The reaction mixture was stirred at 0 °C for 30 min before it was poured into 
8 mL ice-cold water. The mixture was extracted by 3 x 4 mL DCM. The DCM layer was 
washed by brine, dried over MgSO4 and concentrated in vacuo. The crude mixture was 
dissolved in 4 mL DMF, at 0 °C, the solution of potassium thioacetate (84 mg, 0.73 mmol) in 
4 mL DMF was slowly injected. After 1h, the reaction mixture was poured into 50 mL ice 
water and extracted by 50 mL ethyl acetate. The organic layer was washed with brine, dried 
over MgSO4 and concentrated in vacuo. The crude mixture was purified by silica gel 
chromatography to give product 98 (67 mg, 67%) as a colorless oil. [α]23D = -5.7° (c 0.4, 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.85 (d, J = 3.6 Hz, 1H, H1), 4.56 (d, J = 3.5 Hz, 1H, 
H2), 4.22 (t, J = 4.6 Hz, 1H, H4), 4.14 (dt, J = 4.1, 0.7 Hz, 1H, H3), 3.09 (ddd, J = 5.0, 4.2, 2.7 
Hz, 1H, H5), 2.77 (dd, J = 5.0, 4.2 Hz, 1H, H6), 2.69 (dd, J = 4.9, 2.7 Hz, 1H, H6’), 2.40 (s, 3H, 
S-acetyl), 1.51 (s, 3H), 1.31 (s, 3H) (isopropylidene). 13C NMR (101 MHz, CDCl3) δ 193.5 (S-
acetyl), 112.3 (O,O-isopropylidene), 104.7 (C1), 86.0 (C2), 79.1 (C4), 50.7 (C5), 50.3 (C3), 43.5 
(C6), 30.8 (S-acetyl), 26.6, 26.3 (isopropylidene). HRMS m/z [M+Na]+ calcd for C11H16O5NaS 
283.0616, found 283.0615. 
3-S-Pivalyl-5,6-anydro-1,2-O-isopropylidene-β-L-idofuranose (99) 
      Compound 97 (110 mg, 0.54 mmol) and potassium thiopivalate (170 mg, 1.1 mmol) 
were applied to same procedure as the preparation of 98 to give product 99 (108 mg, 67%) as 
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a colorless oil. [α]23D = -6.7° (c 0.6, CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.85 (d, J = 3.6 Hz, 
1H, H1), 4.50 (d, J = 3.6 Hz, 1H, H2), 4.17 (dd, J = 5.3, 4.3 Hz, 1H ,H4), 4.05 (dt, J = 4.2, 0.7 
Hz, 1H, H3), 3.06 (dddd, J = 5.2, 4.3, 2.7, 0.8 Hz, 1H, H5), 2.72 (td, J = 4.6, 0.8 Hz, 1H, H6), 
2.65 (ddd, J = 4.9, 2.7, 0.8 Hz, 1H, H6’), 1.49 (s, 3H), 1.29 (s, 3H), 1.23 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 204.43 (S-pivalyl) 112.2 (O,O-isopropylidene), 104.8 (C1), 86.1 (C2), 79.5 (C4), 
50.7 (C5), 49.7 (C3), 43.5 (C6), 27.2 (S-pivalyl), 26.6, 26.3 (isopropylidene). HRMS m/z 
[M+Na]+ calcd for C14H22O5NaS 325.1086, found 325.1090.  
3-O-(2-Napthyl)methyl-5-O-methanesulfonyl-6-O-benzoyl-1,2-O-isopropyliene-α-D-
allofuranose (102) 
      To a stirred solution of compound 101 (1.01 g, 2.8 mmol) in 20 mL DCM was added 
pyridine (1.2 mL, 4.66 mol) and DMAP (0.017 g, 0.14 mmol). At -30 °C benzoyl chloride 
(0.36 mL, 3.1 mmol) was added dropwise and the reaction mixture was stirred at -30 °C for 1 
h. After completion (monitored by TLC), methanesulfonyl chloride (0.31 mL, 4.1 mmol) was 
added to the reaction mixture at -30 °C. The reaction mixture was stirred at room temperature 
for 10 min before it was concentrated at 40 °C to remove DCM. After DCM was removed, the 
reaction mixture was stirred at room temperature until the completion (monitored by TLC). 
The reaction was diluted with 40 mL DCM and quenched with aqueous NaHCO3. The solution 
was washed with water, brine and dried over MgSO4. The reaction mixture concentrated in 
vacuo and purified by silica gel chromatography to give product 102 (1.02 g, 70%) as a 
colorless oil. [α]23D = +60.0° (c 0.8, CHCl3). 1H NMR (400 MHz, CDCl3) δ 8.14 – 7.99 (m, 
2H), 7.93 – 7.79 (m, 4H), 7.62 – 7.36 (m, 6H), 5.74 (d, J = 3.5 Hz, 1H, H1), 5.28 (dt, J = 8.7, 
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3.1 Hz, 1H, H5), 4.94 (d, J = 11.6 Hz, 1H, NAP CH2), 4.78 (d, J = 11.7 Hz, 1H, NAP CH2), 
4.65 – 4.57 (m, 2H, H2 & H6’), 4.52 (dd, J = 12.6, 8.6 Hz, 1H, H6), 4.37 (dd, J = 8.9, 2.8 Hz, 
1H, H4), 4.05 (dd, J = 8.9, 4.2 Hz, 1H, H3), 2.95 (s, 3H), 1.62 (s, 3H), 1.37 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.0, 166.0, 134.3, 133.3, 133.2, 129.8, 128.5, 128.0, 127.7, 127.2, 126.3, 
126.2, 125.9, 113.6 (O,O-isopropylidene), 104.1 (C1), 78.1 (C2), 76.0 (C3), 72.5 (NAP CH2), 
62.7 (C6), 38.8 (C5), 26.7, 26.6 (isopropylidene), 20.6 (Acetyl). HRMS m/z [M+Na]+ calcd for 
C28H30O9NaS 565.1508, found 565.1494. 
3-O-(2-Napthyl)methyl-5,6-dideoxy-5,6-epithio-1,2-O-isopropyliene-α-D-allofuranose 
(103) 
      At 0 °C, to a stirred solution of compound 102 (0.54 g, 1.0 mmol) in anhydrous 
methanol (50 mL, 0.02 M) was added NaOMe (64 mg, 1.2 mmol). The reaction was stirred at 
0 °C until the completion of the reaction mixture (monitored by TLC). Amberlyst IR 120 was 
added portionwise to neutralize the reaction mixture (monitored by pH paper). The resin was 
filtered off and thiourea (76 mg, 1 mmol) was added to the reaction mixture. The reaction was 
stirred at 80 °C for 3 h before it was concentrated in vacuo. The residue was dissolved in DCM 
and washed by water, brine and dried over MgSO4 and concentrated in vacuo. The crude 
mixture was concentrated in vacuo and purified by silica gel chromatography to give product 
103 (0.25 g, 70%) as a colorless oil. [α]23D = +74.2° (c 1.2, CHCl3). 1H NMR (400 MHz, CDCl3) 
δ 7.94 – 7.78 (m, 4H), 7.60 – 7.42 (m, 3H), 5.72 (d, J = 3.7 Hz, 1H, H1), 4.95 (d, J = 12.1 Hz, 
1H, NAP CH2), 4.76 (d, J = 12.1 Hz, 1H, NAP CH2), 4.59 (t, J = 4.1 Hz, 1H, H2), 4.01 (dd, J 
= 8.6, 6.2 Hz, 1H, H4), 3.72 (dd, J = 8.6, 4.4 Hz, 1H, H3), 3.04 – 2.93 (m, 1H, H5), 2.47 (dd, J 
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= 6.5, 1.4 Hz, 1H, H6’), 2.39 (dd, J = 5.4, 1.4 Hz, 1H, H6), 1.60 (s, 3H), 1.36 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 134.8, 133.2, 133.1, 128.4, 127.9, 127.8, 126.9, 126.4, 126.3, 126.1, 125.9, 
113.1 (O,O-isopropylidene), 103.8 (C1), 80.7 (C2), 77.6 (C3), 72.3 (NAP CH2), 43.6 (C4), 30.5 
(C5), 26.8, 26.6 (isopropylidene), 20.7 (C6). HRMS m/z [M+Na]+ calcd for C20H22O4SNa 
381.1137, found 381.1138. 
3-O-(2-Napthyl)methyl-5-S-acetyl-6-O-acetyl-1,2-O-isopropyliene-α-D-allofuranose (104) 
      To a stirred solution of compound 103 (0.36 g, 1.0 mmol) in mixture of acetic anhydride 
(20 mL) and glacial acetic acid (4 mL) was added anhydrous potassium acetate (0.49 g, 5.0 
mmol) and refluxed at 145 °C for 12 h. After the reaction mixture was cooled, it was poured 
into ice water and extracted with chloroform (3×10 mL). The choloroform was collected and 
washed with aqueous NaHCO3, brine, dried over MgSO4, and concentrated in vacuo. The 
residue was purified over silica gel chromatography to give 104 (0.26 g, 56%) as a colorless 
oil. [α]23D = +45.5° (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.90 – 7.79 (m, 4H), 7.57 – 
7.40 (m, 3H), 5.69 (d, J = 3.7 Hz, 1H), 4.91 (d, J = 11.9 Hz, 1H), 4.68 (d, J = 11.9 Hz, 1H), 
4.57 (t, J = 4.1 Hz, 1H), 4.34 – 4.25 (m, 2H), 4.20 (dd, J = 11.4, 5.9 Hz, 1H), 4.08 (q, J = 5.6 
Hz, 1H), 3.78 (dd, J = 8.8, 4.4 Hz, 1H), 2.25 (s, 3H), 1.96 (s, 3H), 1.59 (s, 3H), 1.35 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 193.9, 170.5, 134.7, 133.2, 133.1, 128.3, 127.9, 127.7, 126.9, 
126.2, 126.1, 125.9, 113.2 (O,O-isopropylidene), 103.8 (C1), 80.2 (C2), 77.9 (C4), 77.5 (C3), 
72.4 (NAP CH2), 63.3 (C6), 43.6 (C5), 30.5 (S-acetyl), 26.9, 26.6 (isopropylidene), 20.8 
(Acetyl). HRMS m/z [M+Na]+ calcd for C24H28O7SNa 483.1453, found 483.1460. 
3-O-(2-Napthyl)methyl-1,2,4,6-tetra-O-acetyl-5-thio-α,β-D-allopyranose (105) 
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      A solution of compound 104 (460 mg, 1.0 mmol) in 20 mL aqueous acetic acid (50%) 
was stirred at 90 °C for 12 h. The reaction mixture was concentrated in vacuo and co-
evaporated with toluene (3×10 mL) to remove acetic acid. The crude mixture was dissolved in 
anhydrous methanol (300 mL) and NaOMe (3.2 mg, 0.06 mmol) was added at 0 °C. The 
reaction was stirred at 0 °C for 4 h before Amberlyst IR120 resin was added to quench the 
reaction (monitored by pH paper). After reaction mixture was neutralized, the resin was filtered 
off and reaction was concentrated in vacuo. The residue was dissolved in pyridine (10 mL) and 
acetic anhydride (4.6 mL, 0.05 mol) was added at 0 °C. The reaction mixture was stirred at 
room temperature for 12 h before it was concentrated in vacuo. The residue was purified by 
silica gel chromatography to give 105 (227 mg, 45%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.90 – 7.77 (m, 5H), 7.48 (ddt, J = 8.9, 6.8, 1.7 Hz, 5H), 6.30 (d, J = 9.3 Hz, 1H, 
H1β), 6.14 (d, J = 3.7 Hz, 1H, H1α), 5.30 – 5.21 (m, 2H, H4α &H4β), 5.16 (td, J = 10.8, 10.4, 2.3 
Hz, 2H, Η2α &H2β), 4.90 – 4.75 (m, 4H, Nap CH2), 4.45 (dd, J = 12.1, 5.1 Hz, 1H, Η6α’), 4.32 
(dd, J = 12.0, 5.5 Hz, 1H, Η6β), 4.21 – 4.09 (m, 2H, Η6α& Η6β), 3.99 (ddd, J = 10.9, 5.1, 2.7 Hz, 
1H, Η5α), 3.85 (ddd, J = 10.2, 5.4, 3.3 Hz, 1H, Η5β), 2.08 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 
2.03 (s, 3H), 2.01 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.6, 169.9, 169.6, 169.4, 169.1, 
135.8, 134.9, 133.1, 133.0, 128.2, 128.0, 127.9, 127.7, 126.8, 126.3, 126.2, 126.0, 125.6, 75.6 
(C1α), 75.4 (C1β), 74.0 (C2), 72.6 (NAP CH2), 72.5 (NAP CH2), 71.9, 70.6 (C4α), 70.1 (C4β), 
61.7 (C6α), 61.2 (C6β), 40.0 (C5α), 35.6 (C5β), 21.1, 20.7. HRMS m/z [M+Na]+ calcd for 
C25H28O9SNa 527.1352, found 527.1354. 
 71 
4,6-O-Benzylidene-3-O-(2-napthyl)methyl-1,2-di-O-acetyl-5-thio-α,β-D-allopyranose 
(106) 
      To a solution of compound 105 (171 mg, 0.34 mmol) in 10 mL anhydrous MeOH was 
added NaOMe (3.2 mg, 0.06 mmol). The reaction mixture was stirred at room temperature 
until the completion and Amberlyst IR 120 was added to neutralize the reaction mixture. The 
reaction mixture was filtered and concentrated in vacuo and was re-dissolved in 4 mL 
anhydrous MeCN. To the reaction mixture was added camphorsulfonic acid (8.0 mg, 0.03 
mmol) and benzaldehyde dimethyl acetal (258 mg, 1.70 mmol). The reaction mixture was 
stirred at room temperature for 25 min before aqueous NaHCO3 was added. The reaction 
mixture was extracted by 3 x 10 mL ethyl acetate, the organic layer was washed with brine, 
dried over MgSO4 and concentrated in vacuo. The crude mixture was acetylated and purified 
by silica gel chromatography to give product 106 (66 mg, 46%) as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 7.90 – 7.70 (m, 6H), 7.60 – 7.34 (m, 11H), 6.36 (d, J = 9.8 Hz, 1H, H1β), 
6.12 (d, J = 3.6 Hz, 1H, H1α), 5.66 (s, 1H, α isomer benzylidene), 5.60 (s, 1H, β isomer 
benzylidene), 5.22 – 5.15 (m, 2H, H2α & H2β), 5.12 (d, J = 12.2 Hz, 1H, α isomer NAP CH2), 
5.02 (d, J = 12.0 Hz, 1H, β isomer NAP CH2), 4.83 (dd, J = 12.1, 6.3 Hz, 2H, α,β isomers NAP 
CH2), 4.31 (ddd, J = 11.6, 7.3, 4.6 Hz, 1H, H6α), 4.26 – 3.99 (m, 4H, H3 &H4 &H6β), 3.94 – 
3.87 (m, 1H, H5β), 3.76 (td, J = 11.1, 4.5 Hz, 1H, H5α), 2.13 (s, 3H), 2.07 (s, 3H, β isomer 
acetate), 1.97 (s, 3H), 1.87 (s, 3H, β isomer acetate). 13C NMR (101 MHz, CDCl3) δ 170.1, 
169.8, 169.0, 137.6, 136.5, 133.2, 132.8, 129.3, 128.4, 128.0, 127.9, 127.7, 127.0, 126.3, 126.2, 
126.1, 126.0, 125.8, 125.7, 102.1 (Benzylidene), 82.4 (C1α), 82.3 (C1β), 75.1 (C4), 74.9(C2α), 
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74.5 (C2β), 72.1 (NAP CH2), 70.7 (C3α), 70.1 (C3β), 68.5 (C6), 35.2, 31.8(C5α), 31.6(C5β), 22.7, 
21.2, 20.8. HRMS m/z [M+Na]+ calcd for C28H28O7SNa 531.1453, found 531.1454. 
4,6-O-Benzylidene-1,2-di-O-acetyl-5-thio-α,β-D-allopyranose (107) 
      To a solution of compound 106 (68 mg, 0.13 mmol) in 10 mL DCM and 2.5 mL MeOH 
was added DDQ (92 mg, 0.40 mmol). The reaction was stirred at room temperature for 
overnight before aqueous NaHCO3 was added to quench the reaction. The reaction mixture was 
extracted into DCM and washed by water, brine and dried over MgSO4. The crude mixture was 
concentrated in vacuo and purified by silica gel chromatography to give product 107 (41 mg, 
83%) as a colorless oil. α:1H NMR (400 MHz, CDCl3) δ 7.49 (dd, J = 6.8, 2.9 Hz, 2H), 7.38 
(dd, J = 5.2, 2.0 Hz, 3H), 6.08 (d, J = 3.6 Hz, 1H, H1), 5.70 (s, 1H, benzylidene), 5.21 (t, J = 
3.3 Hz, 1H, H2), 4.38 – 4.30 (m, 2H, H3 & H6), 4.02 (dd, J = 9.8, 2.3 Hz, 1H, H4), 3.86 (td, J = 
10.5, 9.9, 4.3 Hz, 1H, H5), 3.77 (t, J = 11.0 Hz, 1H, H6), 2.51 (s, 1H, OH), 2.18 (s, 3H), 2.13 
(s, 3H). β:1H NMR (400 MHz, CDCl3) δ 7.52 – 7.44 (m, 2H), 7.42 – 7.33 (m, 3H), 6.33 (d, J 
= 9.8 Hz, 1H, H1), 5.65 (s, 1H, benzylidene), 5.26 (dd, J = 9.8, 2.6 Hz, 1H, H2), 4.43 – 4.36 (m, 
1H, H3), 4.35 – 4.26 (m, 1H, H4), 3.98 (dd, J = 9.4, 2.1 Hz, 1H, H6’), 3.82 – 3.69 (m, 2H, 
H5&H6), 2.30 (bs, 1H, OH), 2.12 (s, 3H), 2.08 (s, 3H).  α:13C NMR (101 MHz, CDCl3) δ 
169.7, 169.6, 137.1, 129.4, 128.4, 126.2, 102.0 (Benzylidene), 81.3 (C1), 71.3 (C2), 71.2 (C4), 
69.4 (C3), 68.3 (C6), 30.8 (C5), 21.2, 20.9. β: 13C NMR (101 MHz, CDCl3) δ 129.3, 128.4, 
126.0, 101.8 (Benzylidene), 81.2 (C1), 73.9 (C2), 70.3 (C4), 69.5 (C3), 68.4 (C6), 34.6 (C5), 20.9, 
20.7. HRMS m/z [M+Na]+ calcd for C17H20NaO7S 391.0827 found 391.0823 
4,6-O-Benzylidene-3-S-acetyl-1,2-di-O-acetyl-3,5-dithio-α,β-D-glucopyranose (108) 
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      To a solution of compound 107 (73 mg, 0.20 mmol) in DCM 10 mL was added pyridine 
(0.12 mL, 1.42 mmol). At 0 °C, trifluoromethanesulfonic anhydride (0.12 mL, 0.71 mmol) was 
added dropwise. The reaction mixture was stirred at 0 °C for 30 min before it was poured into 
8 mL ice-cold water. The mixture was extracted by 3 x 4 mL DCM. The DCM layer was 
washed by brine, dried over MgSO4 and concentrated in vacuo. The crude mixture was 
dissolved in 4 mL DMF, at 0 °C, the solution of potassium thioacetate (84 mg, 0.73 mmol) in 
4 mL DMF was slowly injected. After 1h, the reaction mixture was poured into 50 mL ice 
water and extracted by 50 mL ethyl acetate. The organic layer was washed with brine, dried 
over MgSO4 and concentrated in vacuo. The crude mixture was purified by silica gel 
chromatography to give product 108 (56 mg, 66%) as a colorless oil. β: 1H NMR (400 MHz, 
CDCl3) δ 7.48 – 7.29 (m, 5H), 5.97 (d, J = 8.2 Hz, 1H, H1), 5.58 (s, 1H, Benzylidene), 5.36 (t, 
J = 8.2 Hz, 1H, H2), 4.27 (dd, J = 11.1, 4.6 Hz, 1H, H6 equatorial), 3.94 (t, J = 10.1 Hz, 1H, H4), 
3.84 (dd, J = 10.5, 8.3 Hz, 1H, H3), 3.73 (t, J = 11.0 Hz, 1H, H6 axial), 3.33 (ddd, J = 11.0, 9.7, 
4.6 Hz, 1H, H5), 2.33 (s, 3H, S-acetyl), 2.09 (s, 3H, O-acetyl), 2.06 (s, 3H, O-acetyl). α:1H 
NMR (400 MHz, CDCl3) δ 7.52 – 7.31 (m, 5H), 6.10 (d, J = 3.0 Hz, 1H, H1), 5.61 (s, 1H, 
Benzylidene), 5.31 – 5.22 (m, 1H, H2), 4.25 (dd, J = 10.9, 4.5 Hz, 1H, H6 equatorial), 4.21 – 4.12 
(m, 1H, H3), 3.93 (dd, J = 10.9, 9.6 Hz, 1H, H4), 3.73 (t, J = 11.2 Hz, 1H, H6 axial), 3.61 – 3.50 
(m, 1H, H5), 2.33 (s, 3H, S-acetyl), 2.21 (s, 3H, O-acetyl), 2.01 (s, 3H, O-acetyl). β:13C NMR 
(101 MHz, CDCl3) δ 193.1, 169.4, 168.7, 137.1, 129.1, 128.2, 126.0, 101.7 (Benzylidene), 80.3 
(C1), 73.1 (C2), 73.0 (C4), 68.6 (C6), 48.4 (C3), 40.1 (C5), 30.5 (S-acetyl), 20.7, 20.6. α:13C 
NMR (101 MHz, CDCl3) δ 193.5, 169.7, 169.2, 137.2, 129.0, 128.2, 125.9, 101.7 
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(Benzylidene), 81.0 (C1), 71.9 (C2), 70.8 (C4), 68.3 (C6), 46.0 (C3), 38.1 (C5), 30.8 (S-acetyl), 
21.0, 20.6. HRMS m/z [M+Na]+ calcd for C19H22NaO7S2 449.0705, found 449.0710. 
2,6-Di-O-acetyl-3-S,4-O-benzylidene-3,5-dithio-α-D-glucopyranosyl bromide (109) 
      At 0°C, to a stirred solution of compound 108 (28.5 mg, 0.07 mmol) in DCM (2 mL) 
was added 33% HBr / AcOH (0.08 mL). The reaction was stirred at room temperature overnight 
and concentrated in vacuo. The crude mixture was purified by silica gel chromatography to 
give product 109 (11.4 mg, 39%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.31 
(m, 5H), 6.18 (s, 1H, O,S-benzylidene), 5.72 (d, J = 3.4 Hz, 1H, H1), 4.80 (dd, J = 10.7, 3.3 
Hz, 1H, H2), 4.60 (dd, J = 12.0, 3.5 Hz, 1H, H6), 4.29 (dd, J = 12.0, 6.7 Hz, 1H, H6’), 4.18 – 
3.91 (m, 2H, H3 & H4), 3.76 (ddd, J = 10.0, 6.7, 3.5 Hz, 1H, H5), 2.10 (S, 3H), 2.08 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.4, 169.7, 138.8, 129.2, 128.6, 126.9, 85.5 (C4), 85.3 (S,O-
benzylidene), 76.2 (C2), 62.1 (C6), 54.5 (C1), 51.8 (C3), 42.7 (C5), 20.7 (O-Acetyl). HRMS m/z 
[M+Na]+ calcd for C17H19BrNaO5S2 468.9755, found 468.9757. 
1,2,4,6-Tetra-O-acetyl-5-thio-α,β-D-allopyranose (110) 
      To a solution of compound 105 (115 mg, 0.23 mmol) in 20 mL DCM and 5 mL MeOH 
was added DDQ (92 mg, 0.40 mmol). The reaction was stirred at room temperature for 
overnight before aqueous NaHCO3 was added to quench the reaction. The reaction mixture was 
extracted into DCM and washed by water, brine and dried over MgSO4. The crude mixture was 
concentrated in vacuo and purified by silica gel chromatography to give product 110 (69 mg, 
83%) as a colorless oil.α: 1H NMR (400 MHz, CDCl3) δ 6.09 (d, J = 3.6 Hz, 1H), 5.23 – 5.09 
(m, 2H), 4.43 (dd, J = 12.1, 5.0 Hz, 1H), 4.29 (s, 1H), 4.14 (dd, J = 12.1, 3.0 Hz, 1H), 3.83 
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(ddd, J = 11.0, 4.9, 2.9 Hz, 1H), 2.65 (s, 1H), 2.14 (s, 3H), 2.11 (s, 3H), 2.07 (s, 3H), 2.04 (s, 
3H). β: 1H NMR (400 MHz, CDCl3) δ 6.23 (d, J = 9.0 Hz, 1H), 5.24 (dd, J = 9.0, 2.5 Hz, 1H), 
5.17 (dd, J = 9.9, 2.4 Hz, 1H), 4.39 – 4.26 (m, 2H), 4.17 (dd, J = 11.9, 3.8 Hz, 1H), 3.78 (ddd, 
J = 9.6, 5.5, 3.8 Hz, 1H), 2.45 (s, 1H), 2.11 (s, 3H), 2.09 (s, 3H), 2.07 – 2.05 (m, 6H). α:13C 
NMR (101 MHz, CDCl3) δ 170.57, 169.5, 169.2, 168.9, 72.1, 71.6, 71.1, 69.9, 61.1, 34.6, 21.1, 
20.8, 20.7, 20.6. β:13C NMR (101 MHz, CDCl3) δ 170.6, 169.6, 169.4, 169.0, 73.5, 71.5, 69.7, 
69.2, 61.8, 39.5, 20.8, 20.8, 20.7, 20.6. HRMS m/z [M+Na]+ calcd for C14H20NaO9S 387.0726, 
found 387.0728. 
3-S-Acetyl-1,2,4,6-tetra-O-acetyl-3,5-dithio-α,β-D-glucopyranose (111) 
      To a solution of compound 110 (39 mg, 0.11 mmol) in 5 mL DCM was added 
pyridine (0.06 mL, 0.75 mmol). At 0 °C, trifluoromethanesulfonic anhydride (0.05 mL, 0.32 
mmol) was added dropwise. The reaction mixture was stirred at 0 °C for 30 min before it was 
poured into 8 mL ice-cold water. The mixture was extracted by 3 x 4 mL DCM. The DCM 
layer was washed by brine, dried over MgSO4 and concentrated in vacuo. The crude mixture 
was dissolved in 3 mL DMF, at 0 °C, cesium thioacetate (34 mg, 0.17mmol) added and the 
reaction mixture was stirred at room temperature. After 1h, the reaction mixture was poured 
into 20 mL ice water and extracted by 50 mL ethyl acetate. The organic layer was washed 
with brine, dried over MgSO4 and concentrated in vacuo. The crude mixture was purified by 
silica gel chromatography to give product 111 (25 mg, 55%) as a colorless oil. β: 1H NMR 
(400 MHz, CDCl3) δ 5.90 (d, J = 8.0 Hz, 1H, H1), 5.31 (dd, J = 9.3, 8.0 Hz, 1H, H2), 5.25 (t, 
J = 10.0 Hz, 1H, H4), 4.27 (dd, J = 11.9, 5.8 Hz, 1H, H6’), 4.17 – 4.07 (m, 1H, H6), 3.81 (dd, 
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J = 10.3, 9.3 Hz, 1H, H3), 3.38 (ddd, J = 9.7, 5.7, 4.0 Hz, 1H, H5), 2.33 (s, 3H, S-acetyl), 2.08 
(s, 3H, O-acetyl), 2.06 (s, 3H, O-acetyl), 2.02 (d, J = 1.2 Hz, 6H, O-acetyl). α: 1H NMR (400 
MHz, CDCl3) δ 6.09 (d, J = 3.6 Hz, 1H, H1), 5.19 (dd, J = 3.7, 2.8 Hz, 1H, H2), 5.15 (dd, J = 
11.0, 2.4 Hz, 1H, H4), 4.43 (dd, J = 12.1, 5.0 Hz, 1H, H6), 4.29 (s, 1H), 4.14 (dd, J = 12.1, 3.0 
Hz, 1H, H6’), 3.83 (ddd, J = 11.0, 4.9, 2.9 Hz, 1H), 2.65 (s, 1H). 2.14 (s, 3H), 2.11 (s, 3H), 
2.07 (s, 3H), 2.04 (s, 3H). β: 13C NMR (101 MHz, CDCl3) δ 192.8, 170.5, 169.4, 169.2, 
168.7, 72.8 (C2 & C1), 70.7 (C4), 62.2 (C6), 48.6 (C3), 43.8 (C5), 30.5 (S-acetyl), 20.7 (O-
acetyl), 20.6 (O-acetyl). α:13C NMR (101 MHz, CDCl3) δ 170.5, 169.5, 169.4, 168.9, 72.1 
(C1), 71.6 (C2), 70.0 (C4), 61.1 (C6), 47.6 (C3), 42.5 (C5), 30.6 (S-acetyl), 20.7 (O-acetyl), 
20.6 (O-acetyl), 20.5 (O-acetyl). HRMS m/z [M+Na]+ calcd for C14H19NaO7S2Br 464.9653, 
found 464.9653.  
3-S-Acetyl-1,2,4,6-tetra-O-acetyl-3,5-dithio-α,β-D-glucopyranosyl Bromide (112) 
      Compound 111 (25 mg, 0.06 mmol) was subjected to bromination according to general 
procedure D to give the product 112 (20 mg, 76%) as a colorless oil. α: 1H NMR (400 MHz, 
Chloroform-d) δ 5.53 (d, J = 3.5 Hz, 1H, H1), 5.30 (t, J = 10.7 Hz, 1H, H4), 4.94 (dd, J = 11.2, 
3.5 Hz, 1H, H2), 4.41 (dd, J = 12.2, 4.9 Hz, 1H, H6), 4.23 – 4.04 (m, 2H, H3 & H6’), 3.67 (dd, 
J = 10.4, 1.9 Hz, 1H, H5), 2.34 (s, 3H, S-acetyl), 2.06 (s, 6H), 2.04 (s, 3H). β: [α]23D = -6.3°(c 
1.1, CHCl3).1H NMR (400 MHz, CDCl3) δ 5.36 – 5.21 (m, 2H, H2 & H4), 4.75 (d, J = 9.7 Hz, 
1H, H1), 4.22 (dd, J = 12.1, 5.7 Hz, 1H, H6), 4.17 – 4.08 (m, 1H, H6’), 3.71 (t, J = 10.9 Hz, 1H, 
H3), 3.32 (ddd, J = 10.3, 5.7, 3.3 Hz, 1H, H5), 2.33 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 2.00 (s, 
3H). α: 13C NMR (101 MHz, CDCl3) δ 192.8, 170.5, 169.5, 169.4, 73.3 (C2), 70.4 (C4), 61.1 
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(C6), 54.6 (C3), 47.6 (C1), 42.5 (C5), 30.6 (S-acetyl), 20.7, 20.6, 20.5. β:13C NMR (101 MHz, 
CDCl3) δ 192.9, 170.5, 169.2, 169.0, 75.0 (C2), 70.7 (C4), 61.3 (C6), 51.0 (C3), 48.2 (C1), 45.5 
(C5), 30.5 (S-acetyl), 20.6, 20.5, 20.5. HRMS m/z [M+Na]+ calcd for C14H19NaO7S2Br 
464.9653, found 464.9649.  
3-Deoxy-1,2,4,6-tetra-O-acetyl-3,5-dithio-α,β-D-glucopyranose (113) 
      At 0 °C, to a solution of 111 (52 mg, 0.13 mmol) in 5 mL MeCN was added hydrazine 
monohydrate (8 mg, 0.25 mmol). The reaction mixture was stirred at 0 °C for 1h and quenched 
with acetone. The crude mixture was concentrated in vacuo and purifided by silica gel 
chromatography to give 113 (6.5 mg, 13%) and 114 (20 mg, 45%) as a colorless oil. Compound 
113: 1H NMR (400 MHz, CDCl3) δ 5.82 (d, J = 8.7 Hz, 1H, H1), 5.23 (dd, J = 10.3, 8.7 Hz, 
1H, H2), 5.12 (t, J = 10.2 Hz, 1H, H4), 4.26 (dd, J = 11.9, 5.8 Hz, 1H, H6), 4.13 (dd, J = 11.8, 
3.7 Hz, 1H, H6’), 3.26 (ddd, J = 9.6, 5.7, 3.6 Hz, 1H, H5), 2.86 (q, J = 10.1 Hz, 1H, H3), 2.13 
(s, 3H), 2.10 (s, 3H), 2.07 (d, J = 3.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 170.5, 169.7, 
169.5, 168.9, 75.9 (C1), 73.8 (C2), 72.7 (C4), 62.1 (C6), 46.9 (C5), 44.3 (C3), 20.7, 20.7. HRMS 
m/z [M+Na]+ calcd for C14H20NaO8S2 403.0497, found 403.0495.  
3-Deoxy-2,4,6-tri-O-acetyl-3,5-dithio-α,β-D-glucopyranose (114) 
      Compound 114 was prepared in the previous experiment: 1H NMR (400 MHz, CDCl3) 
δ 5.20 – 5.04 (m, 3H, H1 & H2 & H4), 4.32 (dd, J = 12.0, 5.1 Hz, 1H, H6), 4.07 (dd, J = 12.0, 
3.3 Hz, 1H, H6’), 3.58 (ddd, J = 10.5, 5.2, 3.3 Hz, 1H, H5), 3.44 – 3.31 (m, 1H, H3), 2.16 (s, 
3H), 2.13 (s, 3H), 2.07 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.7, 170.0, 169.9, 74.4 (C2), 
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71.3 (C1 & C4), 61.9 (C6), 43.1 (C3), 39.5 (C5), 20.9, 20.7. HRMS m/z [M+Na]+ calcd for 
C12H28NaO7S2 361.0392, found 361.0395. 
3-S-Acetyl-2,4,6-tri-O-acetyl-3,5-dithio-α-D-glucopyranose (115) 
      To a solution of compound 112 (16 mg, 0.04 mmol) in 10 mL aqueous acetone (50%) 
was added TBAI (66 mg, 0.18 mmol). After the reaction was stirred at room temperature 
overnight, it was diluted with 10 mL ethyl acetate and washed with water, brine and dried over 
MgSO4. The reaction mixture was concentrated in vacuo and purified by silica gel 
chromatography to give product 115 (8.4 mg, 62%) as a colorless oil. [α]23D = +80.7°(c 0.3, 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.27 (t, J = 10.7 Hz, 1H, H2), 5.21 (dd, J = 11.6, 2.8 
Hz, 1H, H4), 5.09 (d, J = 2.8 Hz, 1H, H1), 4.34 (dd, J = 12.0, 5.1 Hz, 1H, H6), 4.21 (t, J = 11.2 
Hz, 1H, H3), 4.06 (dd, J = 12.0, 3.3 Hz, 1H, H6’), 3.69 (ddd, J = 10.6, 5.1, 3.3 Hz, 1H, H5), 2.49 
(s, 1H, OH), 2.33 (s, 3H, S-acetyl), 2.06 (S, 6H), 2.02 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
193.2, 170.6, 169.6, 169.5, 74.1 (C1 & C2), 71.3 (C4), 61.8 (C6), 46.2 (C3), 39.5 (C5), 30.6 (S-
acetyl), 20.8, 20.7, 20.5. HRMS m/z [M+Na]+ calcd for C14H20NaO8S2 403.0497, found 
403.0497.  
3-S-Acetyl-2,4,6-tri-O-acetyl-3,5-dithio-α-D-glucopyranosyl Trichloroacetimidate (116) 
      To a solution of compound 115 (16 mg, 0.04 mmol) in 2 mL DCM was added 
trichloroacetonitrile (6 mg, 0.4 mmol). At 0 °C, DBU (6 mg, 0.04 mmol) was added into 
reaction mixture and the reaction mixture was stirred for 30 min before it was concentrated in 
vacuo. The crude mixture was purified by basified silica gel chromatography to give product 
119 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H, trichloroacetimidate NH), 
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6.31 (d, J = 3.0 Hz, 1H, H1), 5.42 – 5.25 (m, 2H, H2 & H4), 4.35 (dd, J = 12.1, 4.9 Hz, 1H, H6’), 
4.23 (t, J = 11.3 Hz, 1H, H3), 4.06 (dd, J = 12.1, 3.2 Hz, 1H, H6), 3.66 – 3.58 (m, 1H, H5), 2.33 
(s, 3H, S-acetyl), 2.06 (s, 3H), 2.04 (s, 3H), 1.98 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 192.8 
(trichloroacetimidate), 170.5, 169.5, 169.4, 160.8, 75.5 (C1), 72.7 (C2), 70.6 (C4), 61.4 (C6), 
46.8 (C3), 41.1 (C5), 30.6 (S-acetyl), 20.6, 20.5. HRMS m/z [M+Na]+ calcd for 
C16H20NCl3NaO8S2 545.9594, found 545.9597. 
3-O-(2-Naphthyl)methyl-1,2-O-isopropylidene-5-S,6-O-isopropylidene-α-D-allofuranose 
(117) 
      To a solution of compound 105 (13 mg, 0.04 mmol) in anhydrous acetone was added 
p-toluenesulfonic acid (9 mg, 0.05 mmol). The reaction was stirred at room temperature 
overnight before NaHCO3 was added to quench the reaction. The reaction mixture was 
extracted into ethyl acetate and washed with water, brine and dried over MgSO4. The crude 
mixture was concentrated in vacuo and purified by silica gel chromatography to give product 
117 (12 mg, 73%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.88 – 7.74 (m, 4H), 7.53 
– 7.40 (m, 3H), 5.94 (d, J = 3.8 Hz, 1H, H1), 4.78 (d, J = 11.5 Hz, 1H, NAP CH2), 4.69 (d, J = 
11.5 Hz, 1H, NAP CH2), 4.63 (d, J = 3.8 Hz, 1H, H2), 4.41 (dd, J = 9.9, 2.5 Hz, 1H, H6), 4.27 
(dd, J = 10.4, 3.2 Hz, 1H), 4.16 (dd, J = 9.9, 5.0 Hz, 1H, H6’), 4.02 (d, J = 3.2 Hz, 1H, H3), 3.87 
(ddd, J = 10.4, 4.9, 2.4 Hz, 1H, H5), 1.68 (s, 3H), 1.62 (s, 3H), 1.52 (s, 3H), 1.32 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 155.2, 133.2, 128.7, 128.2, 127.9, 127.7, 127.0, 126.2, 113.1(O,O-
isopropylidene), 103.9 (C1), 92.6 (S,O-isopropylidene), 80.0 (C2), 79.4 (C3), 77.8 (C4), 72.6 
(NAP CH2), 71.1 (C6), 52.7 (C5), 31.0, 30.6, 26.9, 26.6 (isopropylidene). 
 80 
3-O-Trifluoromethanesulfonyl-1,2-O-5-S,6-O-di-isopropylidene-5-thio-α-D-allofuranose 
(119) 
      At 0 °C, to a stirred solution of compound 118 (2.0 g, 7.2 mmol) and pyridine (5.8 mL, 
72 mmol) was added trifluoromethanesulfonic anhydride (1.8 mL, 10.8 mmol) dropwise. The 
reaction mixture was stirred at 0 °C for 30min before ice cold aqueous NaHCO3 was added. 
The reaction mixture was diluted in DCM, washed by water, brine and dried over MgSO4. The 
reaction mixture was concentrated in vacuo and purified by silica gel chromatography with 
eluent (10 : 1 = Hexane : Ethyl Acetate) to give product 119 as a white solid (2.5 g, 85%). m.p. 
79-80 °C. [α]23D = +15.0° (c 0.6, CHCl3). 1H NMR (600 MHz, CDCl3) δ 5.78 (d, J1, 2 = 3.9 Hz, 
1H, H1), 4.87 (dd, J3,4 = 7.6 Hz, J3,2 = 5.3 Hz, 1H, H3), 4.73 (t, J = 4.6 Hz, 1H, H2), 4.32 (t, J = 
7.2 Hz, 1H, H4), 4.25 (dd, J6, 6’ = 10.3 Hz, J6, 5 = 2.5 Hz, 1H, H6), 4.13 (dd, J6, 6’ = 10.3 Hz, J6, 
5 = 5.8 Hz, 1H, H6’), 3.79 (m, 1H, H5), 1.69 (s, 3H), 1.60 (s, 3H), 1.56 (s, 3H), 1.36 (s, 3H). 13C 
NMR (151 MHz, CDCl3) δ 118.3 (CF3), 114.2 (isopropylidene C), 103.8 (C1), 93.2 
(isopropylidene C), 83.2 (C3), 79.0 (C4), 77.6 (C2), 70.6 (C6), 51.7 (C5), 30.7, 30.4, 26.8, 26.5 
(isopropylidene CH3). HRMS m/z [M+Na]+ calcd for C13H19O7F3NaS2 431.0422, found 
431.0424. 
1,3-Di-S-acetyl-2,4,6-tri-O-acetyl-1,3,5-trithio-β-D-glucopyranose (120) 
      Compound 112 (161 mg, 0.37 mmol) was applied to general procedure E to give 
product 124 (80 mg, 50%) as a colorless oil. [α]23D = +157.2°(c 0.9, CHCl3).1H NMR (400 
MHz, CDCl3) δ 5.21 (dt, J = 14.7, 10.7 Hz, 2H, H1 & H2), 4.68 (d, J = 10.7 Hz, 1H, H4), 4.24 
(dd, J = 12.0, 5.4 Hz, 1H, H6), 4.10 (dd, J = 12.1, 3.3 Hz, 1H, H6’), 3.76 (t, J = 10.9 Hz, 1H, 
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H3), 3.40 (ddd, J = 9.2, 5.4, 3.2 Hz, 1H, H5), 2.36 (s, 3H), 2.32 (s, 3H), 2.07 – 2.04 (m, 3H), 
2.01 (s, 3H), 1.98 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 192.8, 191.5, 170.5, 169.4, 169.3, 
72.1, 71.9, 70.8, 61.5, 51.8, 47.1, 46.0, 30.5, 30.5, 20.6, 20.5, 20.4. HRMS m/z [M+Na]+ calcd 
for C16H22NaO8S3 461.0375, found 461.0374. 
3-S-Acetyl-2,4,6-tri-O-acetyl-3,5-dithio-β-D-glucopyranosyl-(1 → 3)-1,2-O-5-S,6-O-di-
isopropylidene-3,5-dideoxy-3,5-dithio-α-D-glucofuranose (121) 
      Compound 120 (4.0 mg, 9.0 μmol) and compound 119 (6.5 mg, 16 μmol) was subjected 
to coupling reaction according to general procedure A to give product 121 (2.7 mg, 46%) as a 
colorless oil. [α]23D = -22.8°(c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.85 (d, J = 3.6 Hz, 
1H), 5.22 (t, J = 10.7 Hz, 1H), 5.07 (t, J = 10.7 Hz, 1H), 4.70 (d, J = 3.6 Hz, 1H), 4.39 (dd, J 
= 10.5, 3.9 Hz, 1H), 4.32 (dd, J = 10.0, 2.3 Hz, 1H), 4.25 (dd, J = 12.0, 5.1 Hz, 1H), 4.15 – 
4.02 (m, 2H), 3.96 (d, J = 10.5 Hz, 1H), 3.74 (t, J = 10.9 Hz, 1H), 3.62 (ddd, J = 10.4, 4.9, 2.3 
Hz, 1H), 3.58 (d, J = 4.0 Hz, 1H), 3.22 (ddd, J = 10.2, 5.1, 3.3 Hz, 1H), 2.32 (s, 3H), 2.06 (s, 
3H), 2.03 (d, J = 2.0 Hz, 4H), 1.98 (s, 3H), 1.66 (s, 3H), 1.58 (s, 3H), 1.52 (s, 3H), 1.34 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 193.2, 170.5, 169.3, 169.2, 112.3, 105.3, 92.6, 86.0, 81.4, 73.1, 
72.0, 71.0, 61.6, 53.5, 51.8, 50.6, 50.0, 47.0, 31.6, 31.6, 30.7, 30.6, 26.7, 26.4, 20.7, 20.6, 20.5. 
1-S-Acetyl-2,3,4,6-tetra-O-acetyl-1,5-dithio-β-D-glucopyranose (128) 
      Compound 126 (4.95 g, 12.2 mmol) was subjected to bromination according to general 
procedure D to give an α,β mixture of anomeric bromides. The crude product was subjected to 
thioacylation according to general procedure E to give the α,β mixture of anomeric thioacetate, 
the β isomer is isolated by silica gel chromatography with eluent (Hexane : Ethyl Acetate = 
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3:1) to give 128 (2.36 g, 46%) as a colorless solid. m.p. 121-122 °C. [α]23D = +66.1° (c 0.6, 
CHCl3). 1H NMR (600 MHz, CDCl3) δ 5.26 (dd, J4,5 = 10.7 Hz, J4,3 = 9.6 Hz, 1H, H4), 5.22 
(dd, J2,1 = 11.0 Hz, J2,3 = 9.4 Hz, 1H, H2), 5.08 (t, J = 9.5 Hz, 1H, H3), 4.66 (d, J1,2 = 11.0 Hz, 
1H, H1), 4.25 (dd, J6,6’ = 12.1 Hz, J6,5 = 5.4 Hz, 1H, H6), 4.09 (dd, J6’,6 = 12.1 Hz, J6’,5 = 3.2 
Hz, 1H, H6’), 3.41 – 3.35 (m, 1H, H5), 2.35 (s, 3H, SCOCH3), 2.05 (s, 3H), 2.01 (s, 3H), 1.98 
(s, 3H), 1.97 (s, 3H).13C NMR (151 MHz, CDCl3) δ 191.4 (SCOCH3), 170.5, 169.5, 169.3 
(OCOCH3), 74.4 (C3), 72.4 (C2), 71.5 (C4), 61.0 (C6), 44.9 (C1), 44.0 (C5), 30.5 (SCOCH3), 
20.6, 20.5, 20.4, 20.4 (OCOCH3). HRMS m/z [M+Na]+ calcd for C16H22O9NaS2 445.0603, 
found 445.0605. 
2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-1,2-O-5-S,6-O-di-
isopropylidene-3,5-dideoxy-3,5-dithio-α-D-glucofuranose (130) 
      Compound 128 (0.66 g, 1.5 mmol) and 119 (0.73 g, 1.8 mmol) was subjected to 
coupling according to general procedure A. The crude mixture was purified by silica gel 
chromatography with eluent (1 : 4 = Ethyl Acetate : Hexane) to give product 130 (0.75 g, 78%) 
as a colorless solid. m.p. 161-162 °C. [α]23D = +20.0° (c 0.6, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 5.85 (d, J1b, 2b = 3.6 Hz, 1H, H1b), 5.29 (dd, J4a, 5a = 10.7 Hz, J4a, 3a = 9.3 Hz, 1H, H4a), 
5.13 (dd, J2a, 1a = 10.6 Hz, J2a, 3a = 9.4 Hz, 1H, H2a), 5.05 (t, J = 9.4 Hz, 1H, H3a), 4.69 (d, J2b, 
1b = 3.6 Hz, 1H, H2b), 4.39 (dd, J4b, 5b = 10.5 Hz, J4b, 3b = 4.0 Hz, 1H, H4b), 4.34 – 4.26 (m, 2H, 
H6a&6b), 4.15 – 4.06 (m, 2H, H6’a&6’b), 3.98 (d, J1a, 2a = 10.6 Hz, 1H, H1a), 3.65– 3.60 (m, 1H, 
H5b), 3.57 (d, J3b, 4b = 4.0 Hz, 1H, H3b), 3.23 – 3.18 (m, 1H, H5a), 2.07 (s, 3H), 2.06 (s, 3H), 
2.01 (s, 3H), 1.99 (s, 3H), 1.66 (s, 3H), 1.59 (s, 3H), 1.53 (s, 3H), 1.34 (s, 3H). 13C NMR (101 
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MHz, CDCl3) δ 170.5, 169.7, 169.3, 169.2 (OCOCH3), 112.3 (isopropylidene C), 105.3 (C1b), 
92.7 (isopropylidene C), 86.0 (C2b), 81.4 (C4b), 74.5 (C3a), 73.7 (C2a), 72.0 (C6b), 71.6 (C4a), 
61.0 (C6a), 53.4 (C3b), 50.6 (C5b), 47.9 (C1a), 44.6 (C5a), 31.6, 30.7, 26.7, 26.4 (isopropylidene 
CH3), 20.6, 20.6, 20.5, 20.4 (OCOCH3). HRMS m/z [M+Na]+ calcd for C26H38O12NaS3 
661.1423, found 661.1423. 
5-Thio-β-D-glucopyranosyl-(1 → 3)-1,2-O-5-S,6-O-di-isopropylidene-3,5-dideoxy-3,5-
dithio-α-D-glucofuranose (131) 
      Compound 130 (800 mg, 1.2 mmol) was subjected to deacylation according to general 
procedure B to give the product 131 (590 mg, quantitative) as a colorless solid. [α]23D = +43.7° 
(c 1.4, MeOH).1H NMR (600 MHz, CD3OD) δ 5.87 (d, J1b, 2b = 3.6 Hz, 1H, H1b), 4.89 (d, J2b, 
1b = 3.6 Hz, 1H, H2b), 4.36 (dd, J4b, 5b = 10.5 Hz, J4b, 3b = 3.9 Hz, 1H, H4b), 4.25 (dd, J6b, 6’b = 
9.9 Hz, J6b, 5b = 2.2 Hz, 1H, H6b), 4.09 (dd, J6’b, 6b = 9.9 Hz, J6’b, 5b = 4.8 Hz, 1H, H6’b), 3.89 (dd, 
J6a,6’a = 11.4 Hz, J6a, 5a = 4.3 Hz, 1H, H6a), 3.82 (d, J1a, 2a = 10.2 Hz, 1H, H1a), 3.75 (dd, J6’a, 6a 
= 11.4 Hz, J6’a, 5a = 6.0 Hz, 1H, H6’a), 3.63 (d, J3b, 2b = 3.9 Hz, 1H, H3b), 3.62 – 3.60 (m, 1H, 
H5b) 3.53 (t, J = 9.5 Hz, 1H, H4a), 3.35 (dd, J2a, 1a = 10.3 Hz, J2a, 3a = 8.7 Hz, 1H, 3H, H2a), 3.16 
(t, J = 8.8 Hz, 1H, H3a) 2.90 – 2.86 (m, 1H, H5a) 1.62 (s, 3H), 1.55 (s, 3H), 1.46 (s, 3H), 1.30 
(s, 3H). 13C NMR (151 MHz, CD3OD) δ 111.6 (isopropylidene C), 105.4 (C1b), 91.9 
(isopropylidene C), 85.6 (C2b), 81.1 (C4b), 79.4 (C3a), 76.3 (C2a), 74.8 (C4a), 71.6 (C6b), 61.5 
(C6a), 52.2 (C3b), 50.5 (C5b), 49.6 (C5a), 49.2 (C1a), 30.7, 29.6, 25.5, 25.1 (isopropylidene CH3). 
HRMS m/z [M+Na]+ calcd for C18H30O8S3Na 493.1000, found 493.0999. 
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2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-dideoxy-
3,5-dithio-α,β-D-glucopyranose (132) 
      Compound 130 (590 mg, 1.2 mmol) was deprotected according to general procedure C 
to give the product 132 (830 mg, 91%) as a colorless oil. [α]23D = +94.6° (c 0.1, CHCl3). α:β = 
3:1 from NMR integration of H1b signals. 1H NMR (600 MHz, CDCl3) δ 6.02 (d, J = 3.1 Hz, 
1H, H1bα), 5.84 (d, J = 8.4Hz, 1H, H1bβ), 5.37 (dd, J1,2 = 9.6 Hz, J2,3 = 8.4 Hz, 1H, H2bβ), 5.31 
– 5.21 (m, 2H, H4a& H2bα), 5.15 – 4.94 (m, 3H, H2a& H3a& H4b), 4.36 – 4.01 (m, 5H, H6a,6’a& 
H6b, 6’b& H1a), 3.54 – 3.49 (m, 1H, H5bα), 3.36 – 3.22 (m, 2H, H5a & H3bα), 3.20 – 3.17 (m, 1H, 
H5bβ), 3.05 (t, J = 10.1 Hz, 1H, H3bβ), 2.20 (s, 3H), 2.15 (s, 3H), 2.12 (s, H), 2.08 (s, 3H), 2.05 
(s, 3H), 2.00 (s, 3H), 1.98 (s, 3H). 1.97 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 170.5, 169.7, 
169.2, 169.1, 168.9 (Carbonyl C), 75.8 (C2b), 74.2 (C3a), 73.2 (C2a), 71.8 (C4a), 70.5 (C4b& C1b), 
61.5 (C6b), 61.1 (C6a), 50.3 (C1a), 49.9 (C3b), 44.5 (C5a), 40.6 (C5b), 21.1, 20.8, 20.6, 20.5, 20.4, 
20.3 (Acetyl CH3). HRMS m/z [M+Na]+ calcd for C28H38O16S3Na 749.1220, found 749.1223.  
5-Thio-β-D-glucopyranosyl-(1 → 3)-3,5-dideoxy-3,5-dithio-α,β-D-glucopyranose (133)  
      Compound 132 (20 mg, 0.03 mmol) was subjected to deacetylation according to general 
procedure B to give 133 (8 mg, 75%) as a white solid. [α]23D = +102.8° (c 1.3, H2O). α:β = 4:1 
from NMR integration of C1b signals. 1H NMR (600 MHz, D2O) δ 4.86 (d, J = 3.0 Hz, 1H, 
H1bα), 4.60 (d, J = 8.9Hz, 1H, H1bβ), 3.95 (d, J = 10.4 Hz, 1H, H1a), 3.82 – 3.62 (m, 5H, H2b& 
H6a& H6b), 3.54 – 3.41 (m, 2H, H4a&H4b), 3.34 (dd, J2,1 = 11.8 Hz, J2,3 = 9.8 Hz, 1H, H2a), 3.17 
(t, J = 9.8Hz, 1H, H3a), 3.12 – 3.09 (m, 1H, H5bα), 3.00 (t, J = 10.7 Hz, 1H, H3bα), 2.94–2.91 
(m, 1H, H5bβ), 2.90–2.84 (m, 1H, H5a), 2.67 (t, J = 10.4 Hz, 1H, H3bβ). 13C NMR (151 MHz, 
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D2O) δ 77.8 (C3a), 77.2 (C2bβ) 76.2 (C2a), 75.0 (C1bβ) 74.6 (C2bα), 72.9 (C4a), 72.4 (C1bα), 70.8 
(C4b), 60.7 (C6bβ), 60.5 (C6bα), 60.0 (C6a), 57.5 (C3bβ) 54.4 (C3bα), 48.59 (C1a), 48.56 (C5a), 48.1 
(C5bβ), 43.4 (C5bα). HRMS m/z [M+Na]+ calcd for C12H22O8NaS3 413.0374, found 413.0374.  
2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-dideoxy-
3,5-dithio-α-D-glucopyranosyl bromide (134) 
      Compound 132 (246 mg, 0.34 mmol) was subjected to bromination according to 
general procedure D to give product 134 (184 mg, 73%) as a colorless oil. [α]23D = +112.0° (c 
1.0, CHCl3). 1H NMR (600 MHz, CDCl3) δ 5.44 (d, J1b,2b = 3.4 Hz, 1H, H1b), 5.26 (dd, J4a,3a = 
10.7 Hz, J4a,5a = 9.6 Hz, 1H, H4a), 5.09 (t, J = 10.7 Hz, 1H, H3a), 5.05 (t, J = 10.9 Hz, 1H, H2a), 
5.00 (t, J = 9.5 Hz, 1H, H4a), 4.92 (dd, J2b,3b = 10.9 Hz, J2b,1b = 3.5 Hz, 1H, H2b), 4.36 (dd, J6b,6’b 
= 12.2 Hz, J6b,5b = 4.9 Hz, 1H, H6b), 4.25 (dd, J6a,6’a = 12.0 Hz, J6a,5a = 5.0 Hz, 1H, H6a), 4.13 
(dd, J6a,6’a = 12.1 Hz, J6b,5b = 3.4 Hz, 1H, H6’a), 4.10 – 4.07 (m, 2H, H6’a & H1a), 3.62 – 3.59 (m, 
1H, H5b), 3.37 (t, J = 10.9 Hz, 1H, H3b), 3.27– 3.34 (m, 1H, H5a), 2.20 (s, 3H), 2.15 (s, 3H), 
2.06 (s, 4H), 2.03 (s, 3H), 1.99 (s, 3H), 1.97 (s, 3H), 1.96 (s, 3H) 13C NMR (151 MHz, CDCl3) 
δ 170.5, 169.7, 169.3, 169.2, 169.0, 76.7 (C2b), 74.3(C3a), 73.3 (C2a), 71.6 (C4a), 70.1 (C4b), 
61.1 (C6a), 61.0 (C6b), 54.8 (C3b), 50.7 (C1a), 49.9 (C1b), 44.5 (C5a), 42.4 (C5b), 20.9, 20.8, 20.6, 
20.5, 20.4, 20.3 (OCOCH3). HRMS m/z [M+Na]+ calcd for C26H35O14NaS3Br 769.0270, found 
769.0269. 
2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-1-S-acetyl-2,4,6-tri-O-acetyl-
1,3,5-trideoxy-1,3,5-trithio-β-D-glucopyranose (135) 
 86 
      Compound 134 (67 mg, 0.09 mmol) was used according to general procedure E to give 
135 (60 mg, 89%) as a colorless solid. [α]23D = +43.5° (c 1.0, CHCl3). 1H NMR (600 MHz, 
CDCl3) δ 5.25 (dd, J = 10.7, 9.5 Hz, 1H, H4a), 5.21 (t, J = 10.7 Hz, 1H, H2b), 5.06 (dd, J = 11.0, 
9.5 Hz, 1H, H2a), 4.95 (t, J = 10.7 Hz, 1H, H4b), 4.93 (t, J = 9.5 Hz, 1H, H3a), 4.57 (d, J = 10.7 
Hz, 1H, H1b), 4.23 (dd, J = 12.0, 5.3 Hz, 1H, H6a), 4.18 (dd, J = 12.0, 5.6 Hz, 1H, H6b), 4.13 
(dd, J = 12.0, 3.3 Hz, 1H, H6’a), 4.09 (dd, J = 12.0, 3.2 Hz, 1H, H6’b), 3.99 (d, J = 11.1 Hz, 1H, 
H1a), 3.34 (m, 1H, H5b), 3.16 (m, 1H, H5a), 3.01 (t, J = 10.8 Hz, 1H, H3b), 2.35 (s, 3H, SCOCH3), 
2.12 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 1.99 (s, 3H), 1.98 (s, 3H), 1.95 (s, 3H). 
13C NMR (151 MHz, CDCl3) δ 191.9 (SCOCH3), 170.5, 170.4, 169.7, 169.3, 169.2, 169.1, 
168.9 (OCOCH3), 75.2 (C2b), 74.4 (C3a), 72.9 (C2a), 71.6 (C4a), 70.2 (C4b), 61.6 (C6a), 61.0 
(C6b), 55.1 (C3b), 50.5 (C1a), 47.2 (C5b), 45.8 (C1b), 44.6 (C5a), 30.5 (SCOCH3), 20.8, 20.8, 20.6, 
20.6, 20.4, 20.4, 20.2 (OCOCH3). HRMS m/z [M+Na]+ calcd for C28H38O15NaS4 765.0991, 
found 765.0989.  
2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-dideoxy-
3,5-dithio-β-D-glucopyranosyl-(1 → 3)- 1,2-O-5-S,6-O-di-isopropylidene-3,5-dideoxy-3,5-
dithio-α-D-glucofuranose (136) 
      Compound 135 (615 mg, 0.83 mmol) and 119 (507 mg, 1.24 mmol) were subjected to 
coupling according to general procedure A to give 136 (510 mg, 64%) as white crystals. m.p. 
163-164 °C. [α]23D = +26.5° (c 0.4, CH2Cl2). 1H NMR (600 MHz, CDCl3) δ 5.87 (d, J1c,2c = 3.6 
Hz, 1H, H1c), 5.26 (dd, J4a,5a = 10.7 Hz, J4a,3a = 9.6 Hz, 1H, H4a), 5.16 (t, J = 10.6 Hz, 1H, H2b), 
5.08 (dd, J1a,2a = 11.0 Hz, J2a,3a = 9.5 Hz, 1H, H2a), 5.02 – 4.94 (m, 2H, H4b & H3a), 4.71 (d, 
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J1c,2c = 3.6 Hz, 1H, H2c), 4.39 (dd, J4c,5c = 10.5 Hz, J3c,4c = 4.0 Hz, 1H, H4c), 4.32 (dd, J6c,5c = 
10.0 Hz, J6c,6’c = 2.5 Hz, 1H, H6c), 4.25 (dd, J6a,6’a = 12.0 Hz, J6a,5a = 5.1 Hz, 1H, H6a), 4.22 (dd, 
J6b,6’b = 12.0 Hz, J6b,5b = 5.4 Hz, 1H, H6b), 4.15 – 4.11 (m, 2H, H6’a & H6’c), 4.09 (dd, J6b,6’b = 
12.0 Hz, J6’b,5b = 3.3 Hz, 1H, H6’b), 4.00 (d, J1a,2a = 11.1 Hz, 1H, H1a), 3.83 (d, J1b,2b = 10.6 Hz, 
1H, H1b), 3.64 (m, 1H, H5c), 3.55 (d, J3c, 4c = 4.0 Hz, 1H, H3c), 3.25 – 3.14 (m, 2H, H5a & H5b), 
2.93 (t, J = 10.8 Hz, 1H, H3b), 2.20 (s, 3H), 2.16 (s, 3H), 2.13 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H), 
2.00 (s, 3H), 1.97 (s, 3H), 1.66 (s, 3H), 1.60 (s, 3H), 1.53 (s, 3H), 1.35 (s, 3H). 13C NMR (151 
MHz, CDCl3) δ 170.6, 170.5, 169.8, 169.3, 169.2, 169.1, 168.8, 112.3 (isopropylidene C), 
105.4 (C-1c), 92.7 (isopropylidene C), 86.1 (C2c), 81.4 (C4c), 76.2 (C2b), 74.3 (C3a), 72.6 (C2a), 
72.0 (C6c), 71.9 (C4a), 70.3 (C4b), 61.7 (C6b), 61.2 (C6a), 55.3 (C3b), 53.6 (C3c), 50.7 (C1a), 50.6 
(C5c), 50.1 (C1b), 47.0 (C5b), 44.4 (C5a), 31.6, 30.7, 26.7, 26.5 (Isopropylidene CH3), 21.0, 20.9, 
20.6, 20.5, 20.4, 20.2 (Acetyl CH3). HRMS m/z [M+Na]+ calcd for C38H54O18NaS5 981.1811, 
found 981.1810. 
5-Thio-β-D-glucopyranosyl-(1 → 3)-3,5-dideoxy-3,5-dithio-β-D-glucopyranosyl-(1 → 3)-
1,2-O-5-S,6-O-di-isopropylidene-3,5-dideoxy-3,5-dithio-α-D-glucofuranose (137) 
      Compound 136 (568 mg, 0.59 mmol) was deacetylated according to general procedure 
B to give 137 (394 mg, quantitative) as a colorless solid. [α]23D = +17.2° (c 2.6, MeOH). 1H 
NMR (600 MHz, CD3OD) δ 5.90 (d, J1c,2c = 3.5 Hz, 1H, H-1c), 4.92 (d, J2c,1c = 3.5 Hz, 1H, 
H2c), 4.36 (dd, J4c,5c = 10.5 Hz, J4c,3c = 3.9 Hz, 1H, H4c), 4.25 (dd, J6c,6’c = 10.0 Hz, J6c,5c = 2.1 
Hz, 1H, H6c), 4.10 (dd, J6c,6’c = 9.9 Hz, J6’c,5c = 4.8 Hz, 1H, H6’c), 3.92 (d, J = 10.1 Hz, 1H, H1a), 
3.91 – 3.85 (m, 3H, H-1b, H-6a, H6b), 3.82 (dd, J6b,6’b = 11.5 Hz, J6’b,5b = 5.6 Hz, 1H, H6’b), 
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3.73 (dd, J6’a,6a = 11.4 Hz, J6’a,5a = 6.0 Hz, 1H, H6’a), 3.69 (d, J3c,4c = 3.9 Hz, 1H, H3c), 3.64 – 
3.61 (m, 1H, H5c), 3.55 – 3.47 (m, 2H, H4a & H4b), 3.47 – 3.39 (m, 2H, H2a & H2b), 3.19 (t, J = 
8.9 Hz, 1H, H3a), 2.98 – 2.95 (m, 1H, H5a), 2.93 – 2.90 (m, 1H, H5b), 2.74 (t, J = 10.1 Hz, 1H, 
H3b), 1.62 (s, 3H), 1.56 (s, 3H), 1.46 (s, 3H), 1.32 (s, 3H), (isopropilidene CH3). 13C NMR (151 
MHz, CD3OD) δ 111.6 (isopropylidene C), 105.5 (C1c), 91.9 (isopropylidene C), 85.5 (C2c), 
81.2 (C4c), 79.0 (C3a), 77.9 (C2a), 76.2 (C2b), 74.4 (C4a), 73.0 (C4b), 71.6(C6c), 62.4 (C3b), 61.8 
(C6b), 61.5 (C6a), 52.1(C3c), 51.6 (C5b), 51.4 (C1b), 50.5 (C5c), 49.9 (C5a), 49.5 (C1a), 30.7, 29.7, 
25.6, 25.3 (CH3). HRMS m/z [M+Na]+ calcd for C24H40O11NaS5 687.1072, found 687.1073. 
2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-dideoxy-
3,5-dithio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-dideoxy-3,5-dithio-α,β-D-
glucopyranose (138) 
      Compound 137 (394 mg, 0.59 mmol) was deprotected according to general procedure 
C to give 138 (586 mg, 95%) as a colorless solid. [α]23D = +55.2° (c 0.4, CHCl3). 1H NMR (600 
MHz, CDCl3) α:β = 3:1 from 1HNMR integration of H1c signals, δ 6.03 (d, J1cα, 2cα = 3.1 Hz, 
1H, H1cα), 5.87 (d, J1cβ, 2cβ = 7.1 Hz, 1H, Η1cβ), 5.36 (t, J = 7.1Hz, 1H, H2cβ), 5.28 – 5.23 (m, 
2H, H4a & H2cα), 5.14 – 5.04 (m, 3H, H2b & H2a & H4c), 4.99 – 4.93 (m, 2H, H4b & H3a), 4.30 – 
4.08 (m, 5H, H6a & H6b & H6c), 4.05 (dd, J6c, 6’c = 12.1 Hz, J6’c, 5c = 3.3 Hz, 1H, H6’c), 4.03 – 
3.91 (m, 2H, H1b & H1a), 3.56 – 3.48 (m, 1H, H5cα), 3.37– 3.33 (m, 1H, H5cβ), 3.28 (t, J = 11.5 
Hz, 1H, Η3cα), 3.25 – 3.21 (m, 1H, H5b), 3.17– 3.05 (m, 2H, H5a & H3cβ), 2.93 – 2.86 (m, H3b, 
1H), 2.19 (s, 3H), 2.15 (s, 3H), 2.14 (s, 3H), 2.12 (s, 3H), 2.11 (s, 6H), 2.06 (s, 3H), 2.05 (s, 
3H), 2.04 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H), 1.97 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 
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170.57, 170.54, 170.42, 169.67, 169.23, 169.17, 169.14, 169.10, 168.99, 168.86, 168.72 
(Carbonyl C), 76.2 (C2b), 75.5 (C2cα), 74.8 (C2cβ), 74.2 (C3a), 72.7 (C1cβ), 72.6 (C2a), 71.9 (C4a), 
70.8 (C4cα), 70.5 (C1cα & C4b), 70.2 (C4cβ), 62.8 (C6cβ), 61.8 (C6cα), 61.5 (C6b), 61.1 (C6a), 51.6 
(C1b), 50.8 (C1a), 50.0 (C3cα), 46.6 (C5b), 44.5 (C5a), 42.9 (C5cβ), 40.7 (C5cα), 21.1, 21.0, 20.9, 
20.8, 20.7, 20.7, 20.6, 20.6, 20.5, 20.4, 20.2 (Acetyl CH3). HRMS m/z [M+Na]+ calcd for 
C40H54O22NaS5 1069.1608, found 1069.1613.  
5-Thio-β-D-glucopyranosyl-(1 → 3)-3,5-dideoxy-3,5-dithio-β-D-glucopyranosyl-(1 → 3)-
3,5-dideoxy-3,5-dithio-α,β-D-glucopyranose (139) 
      Compound 138 (20 mg, 0.02 mmol) was deacetylated according to general procedure 
B to give 139 (11 mg, quantitative) as a colorless solid, [α]23D = +78.8° (c 2.6, MeOH). α:β = 
4:1 from 13CNMR integration of C1c signals. 1H NMR (600 MHz, D2O) δ 4.85 (d, J = 2.9 Hz, 
1H, H1cα), 4.59 (d, J = 12.0 Hz, 1H, H1cβ) 3.98 (t, J = 10.9 Hz, 2H, H1a&H1b), 3.83 – 3.64 (m, 
6H, H6a,6’a&H6b,6’b&H6c,6’c), 3.58 – 3.42 (m, 4H, H2b&H4a&H4b&H4c), 3.35 (t, J = 9.0 Hz, 1H, 
H2a), 3.17 (t, J = 9.0 Hz, 1H, H3a), 3.14 – 3.10 (m, 1H, H5c), 3.05 (t, J = 10.7 Hz, 1H, H3c), 
2.95– 2.91 (m, 1H, H5b), 2.90–2.85 (m, 1H, H5a), 2.73 (t, J = 10.4 Hz, 1H, H3b). 13C NMR (151 
MHz, D2O) δ 77.9 (C3a), 77.3 (C2cβ), 76.1 (C2a&C2b), 75.1 (C1cβ), 74.7 (C2cα), 72.8 (C4a), 72.5 
(C1cα), 70.8 (C4b), 70.7 (C4cβ), 70.6 (C4cα), 60.7 (C6cβ), 60.5 (C6cα), 60.4 (C6b), 60.0 (C6a), 59.2 
(C3b), 57.6 (C3cβ), 54.5 (C3cα), 50.6 (C5b), 50.4 (C1b), 48.8 (C1a), 48.9 (C5a), 48.1 (C5cβ), 43.5 
(C5cα). HRMS m/z [M+Na]+ calcd for C18H32O11NaS5 607.0446, found 607.0447 
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2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-dideoxy-
3,5-dithio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-trideoxy-3,5-dithio-α-D-
glucopyranosyl bromide (140) 
      Bromination was performed on compound 138 (53 mg, 0.05 mmol) according to 
general procedure D to give 140 (23 mg, 43%) as a colorless oil. [α]23D = +90.0° (c 0.6, CH2Cl2). 
1H NMR (600 MHz, CDCl3) δ 5.47 (d, J = 3.4 Hz, 1H, H1c), 5.17 – 5.02 (m, 1H, H4a), 5.17 – 
5.02 (m, 3H, H2a&H2b& H3a), 5.01 – 4.89 (m, 3H, H2c&H4b&H4c), 4.34 (dd, J6a,6’a = 12.2 Hz, 
J6a,5a = 5.1 Hz, 1H, H6a), 4.29 – 4.06 (m, 5H, H6’a&H6b&H6’b&H6c&H6’c), 4.00 (d, J = 10.7 Hz, 
1H, H1b), 3.95 (d, J = 10.9 Hz, 1H, H1a), 3.67 – 3.58 (m, 1H, H5c), 3.42 (t, J = 10.9 Hz, 1H, 
H3c), 3.29 – 3.20 (m, 1H, H5b), 3.15 – 3.07 (m, 1H, H5a), 2.97 – 2.85 (m, 1H, H3b). 2.23 (s, 3H), 
2.16 (s, 3H), 2.14 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.00 (s, 3H), 
1.99 (s, 3H), 1.97 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 170.5, 170.4, 169.7, 169.3, 169.2, 
169.1, 169.1, 168.9, 168.6 (Carbonyl C), 76.3 (C2c), 76.2 (C2b), 74.3 (C3a), 72.6 (C2a), 71.9 
(C4a), 70.6 (C4c), 70.4 (C4b), 61.7 (C6c), 61.1 (C6b&C6a), 55.3 (C3b), 55.0 (C3c), 51.6 (C1b), 50.8 
(C1a), 50.6 (C1c), 46.8 (C5b), 44.5 (C5a), 42.6 (C5c), 20.9, 20.8, 20.6, 20.5, 20.4, 20.2 (Acetyl 
CH3). HRMS m/z [M+Na]+ calcd for C37H47O25NaS3Br 1089.0650, found 1089.0653.  
2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-dideoxy-
3,5-dithio-β-D-glucopyranosyl-(1 → 3)-1-S-acetyl-2,4,6-tri-O-acetyl-1,3,5-trideoxy-1,3,5-
trithio-β-D-glucopyranose (141) 
      The anomeric bromide of 140 (34 mg, 0.03mmol) was substituted by potassium 
thioacetate (5mg, 1.5 equiv) according to general procedure E to give 141 (30mg, 90%) as a 
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colorless solid. [α]23D = +99.2° (c 0.6, CHCl3). 1H NMR (600 MHz, CDCl3) δ 5.25 (t, J = 10.9 
Hz, 1H, H4a), 5.22 (t, J =10.6 Hz, 1H, H2c), 5.16 – 5.07 (m, 1H, H2b), 5.05 (dd, J2a,1a = 11.0 Hz, 
J2a,3a = 9.5 Hz, 1H, H2a), 5.00 – 4.93 (m, 4H, H3a&H4b&H4c), 4.60 (d, J1c,2c = 10.6 Hz, 1H, H1c), 
4.28 – 4.09 (m, 6H, H6a,6’a & H6b,6’b& H6c, 6’c), 3.93 (d, J1a, 2a = 11.1 Hz, 1H, H1a), 3.90 (d, J1b, 
2b = 10.6 Hz, 1H, H1b) , 3.37 – 3.34 (m, 1H, H5c), 3.16 – 3.13 (m, 1H, H5b), 3.11 – 3.07 (m, 1H, 
H5a), 3.03 (t, J = 10.7 Hz, 1H, H3c), 2.88 – 2.80 (m, 1H, H3b), 2.38 (s, 3H), 2.13 (s, 6H), 2.12 
(s, 6H), 2.06 (s, 6H), 2.04 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H), 1.97 (s, 3H). 13C NMR (151 MHz, 
CDCl3) δ 192.0, 170.5, 170.4, 169.7, 169.3, 169.1, 168.5 (Carbonyl C), 76.1 (C2c), 75.3 (C2b), 
74.3 (C3a), 72.5 (C2a), 71.8 (C4a), 70.5 (C4c), 70.4 (C4b) 61.7 (C6c), 61.7 (C6b), 61.1 (C6a), 55.3 
(C3b), 54.9 (C3c), 52.4 (C1b), 50.8 (C1a), 47.2 (C5c), 46.8 (C5b), 45.7 (C1c), 44.5 (C5a), 30.5 (S-
Acetyl CH3), 20.8, 20.7, 20.60, 20.5, 20.4, 20.2 (Acetyl CH3). HRMS m/z [M+Na]+ calcd for 
C40H54O21NaS6 1085.1380, found 1085.1383.  
2,3,4,6-Tetra-O-acetyl-5-thio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-dideoxy-
3,5-dithio-β-D-glucopyranosyl-(1 → 3)-2,4,6-tri-O-acetyl-3,5-dideoxy-3,5-dithio-β-D-
glucopyranosyl-(1 → 3)-1,2-O-5-S,6-O-di-isopropylidene-3,5-dideoxy-3,5-dithio-α-D-
glucofuranose (142) 
      Compound 141 (510 mg, 0.48 mmol) and compound 119 (490 mg, 0.72 mmol) were 
subjected to coupling reaction according to general procedure A to give product 142 (283 mg, 
46%) as white crystals. mp 139-140 °C. [α]23D = +31.6° (c 0.3, CHCl3). 1H NMR (600 MHz, 
CDCl3) δ 5.88 (d, J1d,2d = 3.6 Hz, 1H, H1d), 5.27 (t, J = 10.1 Hz, 1H, H4a), 5.17 (t, J = 10.6 Hz, 
1H, H2c), 5.13 – 5.08 (m, 1H, H2b), 5.05 (t, J = 10.3 Hz, 1H, H2a), 5.01 – 4.94 (m, 3H, 
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H3a&H4b&H4c), 4.70 (d, J2d,1d = 3.6 Hz, 1H, H2d), 4.40 (dd, J4d,5d = 10.5 Hz, J4d,3d = 3.9 Hz, 1H, 
H4d), 4.33 (dd, J6d,6’d = 10.1 Hz, J6d,5d = 2.4 Hz, 1H, H6d), 4.29 – 4.18 (m, 3H, H6a&H6b&H6c), 
4.17 – 4.07 (m, 4H, H6’a&H6’b&H6’c&H6’d), 3.94 (d, J1a,2a = 11.1 Hz, 1H, H1a), 3.90 (d, J1b,2b = 
10.3 Hz, 1H, H1b), 3.84 (d, J1c,2c = 10.5 Hz, 1H, H1c), 3.67 – 3.62 (m, 1H, H5d), 3.57 (d, J3d,4d = 
4.0 Hz, 1H, H3d), 3.20 –3.15 (m, 2H, H5b&H5c), 3.11 – 3.08 (m, J = 10.3, 4.1 Hz, 1H, H5a), 2.95 
(t, J = 10.7 Hz, 1H, H3c), 2.88–2.82 (m, 1H, H3b), 2.21 (s, 3H), 2.14 (s, 3H), 2.12 (s, 3H), 2.11 
(s, 3H), 2.06 (s, 6H), 2.05 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H), 1.97 (s, 3H), 1.67 (s, 3H), 1.60 (s, 
3H), 1.53 (s, 3H), 1.35 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 170.6, 170.4, 169.7, 169.2, 
169.1, 168.7, 168.3, 112.3 (isopropylidene C), 105.4 (C1d), 92.7 (isopropylidene C), 86.1 (C2d), 
81.4 (C4d), 76.2 (C2c), 75.7 (C2b), 74.2 (C3a), 72.5 (C2a), 72.0 (C6d), 71.8 (C4a), 70.6 (C4c) 70.4 
(C4b), 61.8 (C6c), 61.7 (C6b), 61.0 (C6a), 55.3 (C3b), 54.9 (C3c), 53.5 (C3d), 52.5 (C1b), 50.8 (C1a), 
50.6 (C5d), 50.0 (C1c), 47.0 (C5c), 46.6 (C5b), 44.5 (C5a), 31.6, 30.7, 26.7, 26.5 (Isopropylidene 
CH3), 21.0, 20.9, 20.8, 20.7, 20.6, 20.5, 20.4, 20.2 (Acetyl CH3). HRMS m/z [M+Na]+ calcd 
for C50H70O24NaS7 1301.2200, found 1301.2205. 
5-Thio-β-D-glucopyranosyl-(1 → 3)-3,5-dideoxy-3,5-dithio-β-D-glucopyranosyl-(1 → 3)-
3,5-dideoxy-3,5-dithio-β-D-glucopyranosyl-(1 → 3)-1,2-O-5-S,6-O-di-isopropylidene-3,5-
dideoxy-3,5-dithio-α-D-glucofuranose (143) 
      Compound 142 (150 mg, 0.12 mmol) was deacetylated according to general procedure 
B to give 143 (100 mg, quantitative) as a colorless solid. [α]23D = +18.9° (c 0.5, MeOH). 1H 
NMR (600 MHz, CD3OD) δ 5.88 (d, J1d,2d = 3.6, 1H, H1d), 4.90 (d, J2d,1d = 3.6 Hz, 1H, H2d), 
4.37 (dd, J4d,5d = 10.5 Hz, J4d,3d = 4.0 Hz, 1H, H4d), 4.25 (dd, J = 10.0, 1.8 Hz, 1H, H6d), 4.10 
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(dd, J = 8.0, 4.9, 1.6 Hz, 1H, H6’d), 4.00 (d, J = 10.0 Hz, 1H, H1b) 3.97 (d, J = 10.3 Hz, 1H, 
H1a), 3.94 – 3.86 (m, 4H, H1c&H6a&H6b&H6c), 3.81 – 3.72 (m, 2H, H6’a&H6’b), 3.72 – 3.67 (m, 
H6’c1H), 3.66 (d, J = 3.9 Hz, 1H, H3d), 3.65 – 3.60 (m, 1H, H5d), 3.56 – 3.43 (m, 5H, 
H4a&H4b&H4c&H2b&H2c), 3.38 (t, J = 10.4 Hz, 1H, H2a), 3.17 (t, J = 8.9 Hz, 1H, H3a), 3.02 – 
2.88 (m, 3H, H5a&H5b&H5c), 2.85 – 2.69 (m, 2H, H3b&H3c), 1.62 (s, 3H), 1.56 (s, 3H), 1.46 (s, 
3H), 1.31 (s, 3H). 13C NMR (151 MHz, CD3OD) δ 111.6 (isopropylidene C), 105.4 (C1d), 92.0 
(isopropylidene C), 85.6 (C2d), 81.1 (C4d), 78.6 (C3a), 77.5 (C2a), 77.0 (C2b), 75.8 (C2c), 73.7 
(C4a), 71.9 (C4b), 71.8 (C4c), 71.6 (C6d), 61.8 (C3b), 61.2 (C6c), 61.1 (C3c), 60.9 (C6a&C6b), 52.5 
(C3d), 51.7 (C5b), 51.4 (C5c), 51.3 (C1b), 51.1 (C1c), 50.5 (C5d), 49.6 (C5a&C1a), 30.7, 29.6, 25.5, 
25.2 (isopropylidene-CH3). HRMS m/z [M+Na]+ calcd for C30H50O14NaS7 881.1143, found 
881.1141. 
5-Thio-β-D-glucopyranosyl-(1 → 3)-3,5-dideoxy-3,5-dithio-β-D-glucopyranosyl-(1 → 3)-
3,5-dideoxy-3,5-dithio-β-D-glucopyranosyl-(1 → 3)-3,5-dideoxy-3,5-dithio-α,β-D-
glucopyranose (144) 
      Compound 143 (100 mg, 0.12 mmol) was deprotected according to general procedure 
C to give product 144 (78 mg, 85%) as a white solid. [α]23D = +36.6° (c 0.5, H2O). α:β = 4:1 
from 13CNMR integration of C1d signals.  1H NMR (600 MHz, D2O) δ 4.86 (d, J = 3.0 Hz, 1H, 
H1dα), 4.58 (d, J = 8.8Hz, 1H, H1dβ) 4.02 – 3.90 (m, 3H, H1a& H1b& H1c), 3.86 – 3.59 (m, 9H, 
H6a,6’a & H6b,6’b & H6c,6’c & H6d,6’d & H2d), 3.57 – 3.37 (m, 6H, H4a & H4b & H4c & H4d, H2b & 
H2c), 3.31 (t, J = 9.0 Hz 1H, H2a), 3.13 (t, J = 9.0 Hz, 1H, H3a), 3.10 – 3.06 (m, 1H, H5d), 3.01 
(t, J = 10.6 Hz, 1H, H3d), 2.96– 2.81 (m, 3H, H5a & H5b & H5c), 2.76 – 2.66 (m, 2H, H3b & H3c). 
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13C NMR (151 MHz, D2O) δ 77.9 (C3a), 77.3 (C2dβ), 76.2 (C2a&C2b&C2c), 75.1 (C1dβ), 74.7 
(C2dα), 72.9 (C4a), 72.5 (C1dα), 70.9 (C4b), 70.8 (C4dβ), 70.6 (C4c&C4dα), 60.6 (C6b & C6c), 60.5 
(C6a), 60.0 (C3c), 59.3 (C3b), 59.2 (C3dβ), 54.5 (C3dα), 50.7 (C1b) 50.6 (C5b & C5c), 50.4 (C1c), 
48.8 (C1a), 48.6 (C5a), 48.1 (C5dβ), 43.5 (C5dα). HRMS m/z [M+Na]+ calcd for C24H42O14NaS7 
801.0517, found 801.0518.  
p-N,N-Dimethylamino benzyl alcohol (150) 
      4-(dimethylamino)benzaldehyde (0.5 g, 3.35 mmol) was dissolved in dry methanol (10 
mL) and added sodium borohydride (NaBH4, 253 mg, 6.70 mmol) at 0 °C.  The reaction 
mixture was stirred at 0 °C for 1 h, later at room temperature for 1 h. Methanol was removed 
on rotavapor, added water (200 mL) and extracted with DCM (2 x 100 mL). The DCM layer 
was washed with water (100 mL), brine solution (50 mL) and dried over Na2SO4. The solvent 
was evaporated and the residue was purified by flash chromatography on silica gel with 6/4 
ethyl acetate/hexane to give the product 150 (430 mg, 85 %) as a colorless oil. 1H NMR (500 
MHz, CDCl3): δ 7.25 (d, 2H, J = 9.5 Hz), 6.73 (d, 2H, J = 8.5 Hz), 4.57 (br, 2H, Benzylic CH2), 
2.95 (s, 6H, Me), 1.48 (bs, 1H, OH) ; 13C NMR (125 MHz, CDCl3) δ: 150.6, 129.1, 128.9, 
112.9, 65.6 (Benzylic CH2), 40.9 (Me). HRMS m/z [M+H]+ calculated for C9H14NO is 
152.1075, found 152.1072. 
4,4'-methylenebis(N,N-dimethylaniline) (151) 
      At 0 °C, to a solution of compound 150 (54 mg, 0.36 mmol) in DMF was added NaH 
(8.6 mg, 0.36 mmol) and p-toluenesulfonyl chloride (103 mg, 0.54 mmol) was added into the 
reaction mixture. The reaction mixture was stirred at room temperature for 2 h before the 
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reaction mixture was quenched with aqueous NH4Cl. The crude mixture was extracted into 
ethyl acetate and washed with water, brine and dried over MgSO4. The crude mixture was 
concentrated in vacuo and purified by silica gel chromatography to give product 151 (50.4 mg, 
56%) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.14-7.08 (m, 4H), 6.76-6.71 (m, 4H), 
3.86 (d, 2H, J = 4.4 Hz, Benzylic CH2), 2.95 (s, 6H), 2.94 (s, 6H); 13C NMR (100 MHz, CDCl3) 
δ: 149.3, 130.6, 129.7, 113.3, 41.2, 40.2. HRMS m/z (M+H)+ calcd for C17H23N2 255.1861, 
found 255.1861. 
p-N,N-Dimethylamino benzyl chloride hydrochloride (152) 
      The solution of p-N,N-dimethyl amino benzyl alcohol (0.85 g, 5.60 mmol) in 3.5 mL 
aqueous HCl (36.6%) was refluxed at 100 °C for 12 h. The reaction mixture was concentrated 
in vacuo and high vacuum evaporation at 45 °C for 4 h to remove water to give product 156 
(0.11 g, 96%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.74 (m, 2H), 7.58 – 7.49 
(m, 2H), 4.58 (s, 2H, benzylic CH2), 3.18 (s, 6H, CH3). 13C NMR (101 MHz, CDCl3) δ 142.6, 
139.9, 130.6, 121.3, 46.6 (Benzylic CH2), 44.6 (Me).  
3-O-(4-Chlorobenzyl)-1,2;5,6-di-O-isopropylidene-α-D-glucofuranose (153) 
      At 0 oC, to a solution of 1,2;5,6-di-O-isopropylidene-α-D-glucofuranose (0.2 g, 0.8 
mmol) in 5 mL DMF was added NaH (40 mg, 1 mmol). The reaction was stirred at 0 oC for 30 
min and 4-chlorobenzyl bromide (0.2 g, 1 mmol) was added into the reaction. The reaction was 
stirred at 0 oC for 3 h before it was quenched with aqueous NH4Cl. The crude mixture was 
extracted into ethyl acetate, washed with water, brine and dried over MgSO4. The crude mixture 
was concentrated in vacuo and purified by sílica gel chromatography to give product 153 (0.24 
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g, 78%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.20 (m, 5H), 5.89 (d, J = 3.7 
Hz, 1H, H1), 4.70 – 4.52 (m, 3H, Benzylic CH2 & H2), 4.34 (dt, J = 8.1, 5.9 Hz, 1H, H4), 4.17 
– 4.06 (m, 2H, H6 & H3), 4.05 – 3.93 (m, 2H, H6’ & H5), 1.49 (s, 3H), 1.42 (s, 3H), 1.37 (s, 3H), 
1.31 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 136.1, 133.6, 129.0, 128.6, 111.9, 109.1 
(isopropylidene), 105.3 (C1), 82.6, 81.7, 81.3, 77.3, 77.0, 76.7, 72.4 (Benzylic CH2), 71.5, 67.5, 
26.8, 26.2, 25.4. 
3-O-(p-N,N-Diethylamino benzyl)-1,2;5,6-di-O-isopropylidene-α-D-glucofuranose (154) 
      To a solution of Tris(dibenzylideneacetone)dipalladium(0) (3.3 mg, 3.6 μmol ), 2-
Dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (2.8 mg, 7.2 μmol), potassium tert-
butoxide (28 mg, 0.25 mmol) and 1,2;5,6-di-O-isopropylidene-D-glucofuranose (110 mg, 0.18 
mmol) in Toluene (2 mL) was added diethyl amine (23 μL, 0.22 mmol). The reaction was 
stirred at 80 °C for 12 h before the reaction mixture was concentrated in vacuo and the crude 
mixture was dissolved in Ethyl Acetate (25 mL) and washed by water, brine and dried over 
Na2SO4. The reaction mixture was concentrated in vacuo and purified by silica gel 
chromatography with eluent (8:1 = Hexane: Ethyl acetate) to give product 154 as a colorless 
oil (88 mg, 82%). [α]23D = -18.4° (c 1.5, CHCl3). 1H NMR (600 MHz, CDCl3) δ 7.18 – 7.14 
(m, 2H), 6.66 – 6.60 (m, 2H), 5.86 (d, J = 3.7 Hz, 1H), 4.54 (d, J = 3.8 Hz, 1H), 4.53 – 4.46 
(m, 2H), 4.37 – 4.28 (m, 1H), 4.15 (dd, J = 7.3, 3.1 Hz, 1H), 4.12 – 4.06 (m, 1H), 4.01 – 3.96 
(m, 2H), 3.33 (q, J = 7.1 Hz, 4H), 1.48 (S, 3H), 1.42 (s, 3H), 1.37 (s, 3H), 1.30 (s, 3H), 1.14 (t, 
J = 7.1 Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 129.6, 111.6, 111.5, 105.3, 82.8, 81.3, 81.3, 
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80.9, 77.2, 77.0, 76.8, 72.7, 72.6, 72.2, 67.4, 67.2, 44.4, 26.9, 26.8, 26.8, 26.7, 26.3, 26.2, 25.5, 
25.4, 12.5. HRMS m/z [M+H]+ calcd for C23H36NO6 422.2543, found 422.2544. 
4-(Methoxymethyl)-N,N-diethyl aniline (155) 
      The compound 154 (53 mg, 0.13 mmol) was dissolved in 2 mL methanol and was 
transferred into a 10 mL vial equipped with a magnetic stir bar. The vial was capped properly 
and placed in the microwave (CEM Discover SP Microwave). The microwave was run at 300 
W, 160 °C and 300 psi for 30 min. The vial was cooled to room temperature and the reaction 
mixture was transferred into round bottom flask and concentrated in vacuo. The residue was 
purified by silica gel column chromatography to give product 155 (24 mg, 98%) as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 7.24 – 7.11 (m, 1H), 6.66 (d, J = 8.6 Hz, 1H), 4.34 (s, 1H), 
3.35 (d, J = 7.5 Hz, 4H), 1.16 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 147.5, 129.6, 
124.6, 111.7, 74.7, 57.5, 44.4, 12.5. HRMS m/z [M+H]+ calcd for C12H20NO 194.1545, found 
194.1541. 
ortho-N,N-Dimethylamino benzyl alcohol (156) 
      To a solution of ortho-amino benzyl alcohol (1.23 g, 10 mmol) in 25 mL DMF was 
added Na2HPO4 (5.11 g, 36 mmol) and methyl iodide (3.4 g, 24 mmol). The reaction mixture 
was stirred at 45 oC for 10 h before it was poured into 200 mL water. The crude mixture was 
extracted into diethyl ether, the organic layer was washed with water, brine and dried over 
MgSO4. The crude mixture was concentrated in vacuo and purified by sílica gel 
chromatography to give product 156 (1.3 g, 86%) as a colorless oil.  1H NMR (400 MHz, 
CDCl3) δ 7.29 – 7.19 (m, 2H), 7.19 – 7.13 (m, 1H), 7.08 (tt, J = 7.3, 1.2 Hz, 1H), 5.60 (s, 1H), 
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4.82 (s, 2H), 2.72 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 151.9, 135.2, 128.4, 128.2, 124.4, 
120.1, 64.9, 44.6. HRMS m/z [M+H]+ calcd for C9H14NO 152.1070, found 152.1071. 
ortho-N,N-Dimethylamino benzyl chloride (157) 
      At 0 oC, to a solution of compound 156 (141 mg, 0.93 mmol) in 3 mL chloroform was 
added SO2Cl2 (222 mg, 1.9 mmol). The reaction mixture was stirred at 0 oC for 4 h and 
concentrated in vacuo to give product 157 (157 mg, 100%) as a yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.68 – 7.64 (m, 1H), 7.57 – 7.45 (m, 3H), 5.27 (s, 2H), 3.34 (s, 6H). 13C NMR (101 
MHz, CDCl3) δ 140.6, 133.4, 131.2, 130.9, 120.9, 47.7, 41.9. 
3-O-(ortho-N,N-Dimethylamino benzyl)-1,2;5,6-di-O-isopropylidene-α-D-glucofuranose 
(158) 
      At 0°C, to a stirred solution of 1,2;5,6-di-O-isopropylidene-α-D-glucofuranose (125 mg, 
0.48 mmol) in DMF (1 mL) was added NaH (104 mg, 2.60 mmol) and ortho-N, N-
dimethylamino benzyl chloride (157 mg, 0.93 mmol). The reaction was stirred overnight before 
aqueous NH4Cl was added to quench the reaction. The reaction mixture was diluted in ethyl 
acetate, washed by water, brine and dried over MgSO4. The reaction mixture was concentrated 
in vacuo and purified by silica gel chromatography with eluent (10 : 1 = hexane : ethyl acetate) 
to give product 158 as a colorless oil (104 mg, 55%). [α]23D = -1.9° (c 1.8, CHCl3). 1H NMR 
(400 MHz, CDCl3) δ 7.45 (dd, J = 7.6, 1.8 Hz, 1H), 7.29 – 7.21 (m, 1H), 7.11 – 7.00 (m, 2H), 
5.89 (d, J = 3.7 Hz, 1H, H1), 4.82 (d, J = 11.8 Hz, 1H, benzyl CH2), 4.71 – 4.63 (m, 2H, H2 & 
benzyl CH2), 4.41 (dt, J = 8.0, 6.1 Hz, 1H, H4), 4.18 (dd, J = 7.7, 3.1 Hz, 1H, H5), 4.14 – 4.05 
(m, 2H, H6 & H3), 4.00 (dd, J = 8.6, 6.0 Hz, 1H, H6’), 2.69 (d, J = 2.0 Hz, 6H, NMe2), 1.51 (s, 
 99 
3H), 1.43 (s, 3H), 1.33 (s, 3H), 1.36 (s, 3H).  13C NMR (101 MHz, CDCl3) δ 131.9, 129.3, 
128.3, 123.0, 118.8, 111.7 (Isopropylidene), 108.9 (Isopropylidene), 105.3 (C1), 82.4 (C2), 82.1 
(C3), 81.4 (C5), 72.5 (C4), 68.1 (Benzyl CH2), 67.4 (C6), 45.1 (NMe2), 26.9, 26.8, 26.3, 25.4 
(Isopropylidene CH3). HRMS m/z [M+H]+ calcd for C21H32NO6 394.2230, found 394.2234. 
Phenyl 4-O-(4-bromobenzyl)-2,3-O-isopropylidene-1-thio-β-L-rhamnopyranoside (160) 
      At 0°C, to a stirred solution of phenyl 2,3-O-isopropylidene-1-thio-β-L-
rhamnopyranoside (512 mg, 1.73 mmol) in DMF (10mL) was added NaH (104 mg, 2.60 mmol) 
and 4-bromobenzyl bromide (513 mg, 2.08 mmol). The reaction was stirred overnight before 
aqueous NH4Cl was added to quench the reaction. The reaction mixture was diluted in ethyl 
acetate, washed by water, brine and dried over MgSO4. The crude mixture was concentrated in 
vacuo and purified by silica gel chromatography with eluent (10 : 1 = hexane : ethyl acetate) 
to give product 162 as a white solid (2.5 g, 85%). mp 123 ~ 125 °C. [α]23D = +84.0° (c 0.3, 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.56 – 7.44 (m, 4H), 7.35 – 7.19 (m, 6H), 5.01 (d, J = 
2.1 Hz, 1H, H1), 4.82 (d, J = 11.8 Hz, 1H, benzyl CH2), 4.59 (d, J = 11.8 Hz, 1H, benzyl CH2), 
4.44 (dd, J = 5.7, 2.2 Hz, 1H, H2), 4.20 (t, J = 5.8 Hz, 1H, H3), 3.33 (t, J = 5.3 Hz, 2H, H4 & 
H5), 1.57 (s, 3H), 1.43 (s, 3H), 1.36 (d, J = 5.5 Hz, 3H, H6).  13C NMR (101 MHz, CDCl3) δ 
137.1, 135.1, 131.4, 130.9, 129.6, 128.9, 127.4, 121.6, 110.5 (Isopropylidene C), 84.0 (C1), 
80.8 (C4), 79.9 (C3), 76.4 (C2), 74.4 (C5), 72.1 (Benzyl C), 28.0, 26.4, 18.5 (C6). HRMS m/z 
[M+Na]+ calcd for C22H25BrO4NaS 487.0555, found 487.0557. 
Phenyl 4-O-(p-N,N-diethylamino benzyl)-2,3-O-isopropylidene-1-thio-β-L-
rhamnopyranoside (161) 
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       To a solution of Tris(dibenzylideneacetone)dipalladium(0) (3.3 mg, 3.6 μmol ), 2-
dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (2.8 mg, 7.2 μmol), potassium tert-
butoxide (28 mg, 0.25 mmol) and compound 160 (110 mg, 0.18 mmol) in Toluene (2 mL) was 
added diethyl amine (23 μL, 0.22 mmol). The reaction was stirred at 80 °C for 12 h before the 
reaction mixture was concentrated in vacuo and the crude mixture was dissolved in ethyl 
acetate (25 mL) and washed by water, brine and dried over Na2SO4. The reaction mixture was 
concentrated in vacuo and purified by silica gel chromatography with eluent (8:1 = Hexane: 
Ethyl acetate) to give product 161 as a colorless oil (88 mg, 82%). [α]23D = +14.0° (c 0.2, 
CHCl3).1H NMR (600 MHz, CDCl3) δ 7.55 – 7.48 (m, 2H), 7.33 – 7.21 (m, 3H), 7.21 – 7.14 
(m, 2H), 6.63 (d, J = 8.6 Hz, 2H), 5.00 (d, J = 2.1 Hz, 1H, H1), 4.73 (d, J = 10.8 Hz, 1H, benzyl 
CH2), 4.50 (d, J = 10.8 Hz, 1H, benzyl CH2), 4.42 (dd, J = 5.8, 2.1 Hz, 1H, H2), 4.22 (t, J = 5.9 
Hz, 1H, H, H3), 3.40 – 3.27 (m, 6H, H4 & H5 & Ethyl CH2), 1.60 (s, 3H), 1.43 (s, 3H), 1.36 – 
1.30 (m, 3H, H6), 1.17 – 1.08 (m, 5H). 13C NMR (151 MHz, CDCl3) δ 147.6, 135.3, 130.7, 
130.0, 128.9, 127.2, 124.4, 111.6, 110.4 (isopropylidene C), 84.0 (C1), 80.1 (C4), 79.7 (C3), 
76.3 (C2), 74.8 (C5), 73.2 (Benzyl C), 44.4 (PDMAB Ethyl CH2), 27.9 (CH3), 26.4 (CH3), 18.6 
(C6), 12.5 (PDMAB Ethyl CH3). HRMS m/z [M+H]+ calcd for C26H36NO4S 458.2360, found 
458.2362 
Methyl 6-O-(4-O-(p-N,N-diethylamino benzyl)-2,3-O-isopropylidene-α-L-rhamnosyl)-
2,3,4-tri-O-benzyl-α-D-glucopyranoside (162) 
       To a solution of compound 161 (50 mg, 0.11 mmol), methyl 2,3,4-tri-O-benzyl-α-D-
glucopyranoside (50 mg, 0.11 mmol), NIS (50 mg, 0.22 mmol) and cyclohexene (0.11 mL, 1.1 
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mmol) in anhydrous DCM (1.0 mL) was added activated 4 Å molecular sieve (200 mg). The 
reaction mixture was stirred at room temperature overnight. The reaction temperature was 
cooled to -78 °C and TMSOTf (4.0 μL, 0.02 mmol) was injected into reaction mixture. The 
reaction was stirred at -78 °C for 12 h before it was quenched by triethylamine at-78 °C. The 
reaction mixture was warmed to room temperature and filtered. After filtration, the organic 
layer was washed with aqueous Na2S2O3 and brine and dried over MgSO4 The crude mixture 
was concentrated and purified by sílica gel chromatography to give glycosylation product 162 
(20 mg, 22%) as a colorless oil. [α]23D = +6.4° (c 0.5, CHCl3).1H NMR (600 MHz, CDCl3) δ 
7.39 – 7.22 (m, 12H), 7.18 (d, J = 8.1 Hz, 2H), 6.63 (d, J = 8.1 Hz, 2H), 4.98 (d, J = 10.9 Hz, 
1H, Benzyl CH2), 4.91 – 4.69 (m, 6H, Benzyl CH2 & Rha H1), 4.65 (d, J = 12.1Hz, 1H, Benzyl 
CH2), 4.55 (ddd, J = 6.8, 3.7, 1.7 Hz, 2H, Glc H1 & Benzyl CH2), 4.50 – 4.42 (m, 1H, Benzyl 
CH2), 4.20 (ddd, J = 7.1, 4.4, 1.5 Hz, 1H, Rha H2), 4.04 (dd, J = 5.7, 1.6 Hz, 1H, Rha H3), 4.00 
– 3.94 (m, 1H, Glc H3), 3.84 – 3.78 (m, 1H, Glc H6), 3.72 – 3.61 (m, 2H, Glc H6’ & Rha H4), 
3.53 – 3.42 (m, 3H, Glc H4 & Glc H2 & Glc H6), 3.36 – 3.29 (m, 7H, Glc OMe & PEMAB 
Ethyl CH2), 3.17 (ddt, J = 9.9, 7.2, 1.6 Hz, 1H, Rha H5), 1.51 (s, 3H, isopropylidene), 1.35 (s, 
3H, isopropylidene), 1.20 (dt, J = 6.3, 1.6 Hz, 3H, Rha H6), 1.13 (tt, J = 7.0, 1.6 Hz, 7H, 
PEMAB Me). 13C NMR (151 MHz, CDCl3) δ 147.5, 138.7, 138.1, 131.4, 129.9, 128.5, 128.4, 
128.3, 128.1, 128.0, 127.9, 127.8, 127.6, 124.8, 112.5, 111.6, 109.0 (Isopropylidene C), 97.8 
(Glc C1), 97.1 (Rha C1), 82.1 (Glc C3), 80.5 (Rha C5), 80.0 (Glc C2), 78.8 (Rha C3), 77.5 (Glc 
C4), 75.9 (Rha C2), 75.7 (Benzyl CH2), 74.9 (Benzyl CH2), 73.3 (Benzyl CH2), 69.8 (Glc C5), 
65.8 (Glc C6), 64.7 (Rha C4), 55.1 (Glc OMe), 44.4 (PDEAB Ethyl CH2), 28.0 (Isopropylidene 
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Me), 26.4 (Isopropylidene Me),17.7 (Rha C6), 12.5 (PDEAB Ethyl CH3). HRMS m/z [M+H]+ 
calcd for C48H62NO10 812.4374, found 812.4375. 
Methyl 6-O-(2,3-O-isopropylidene-α-L-rhamnosyl)-2,3,4-tri-O-benzyl-α-D-
glucopyranoside (163) 
Compound 162 (9 mg, 0.01 mmol) was dissolved in 2 mL methanol and was transferred 
into a 10 mL vial equipped with a magnetic stir bar. The vial was capped properly and placed 
in the microwave (CEM Discover SP Microwave). The microwave was run at 300 W, 180 °C 
and 300 psi for 30 min. The vial was cooled to room temperature and the reaction mixture was 
transferred into round bottom flask and concentrated in vacuo. The residue was purified by 
silica gel column chromatography to give product 163 (5.3 mg, 73%) as a colorless oil. [α]23D 
= +9.6° (c 0.3, CHCl3). 1H NMR (600 MHz, CDCl3) δ 7.38 – 7.23 (m, 16H), 4.99 (d, J = 10.8 
Hz, 1H, Benzyl CH2), 4.88 (d, J = 11.0 Hz, 1H, Benzyl CH2), 4.83 – 4.74 (m, 3H, Benzyl CH2 
and Rha H1), 4.66 (d, J = 12.1 Hz, 1H, Benzyl CH2), 4.59 (d, J = 3.5 Hz, 1H, Glc H1), 4.56 (d, 
J = 11.0 Hz, 1H, Benzyl CH2), 4.08 (t, J = 6.3 Hz, 1H, Rha H2), 4.04 (d, J = 5.9 Hz, 1H, Rha 
H3), 3.99 (t, J = 9.3 Hz, 1H, Glc H3), 3.85 (dd, J = 10.7, 2.0 Hz, 1H, Glc H6’), 3.76 – 3.65 (m, 
2H, Glc H5 & Rha H4), 3.54 (dd, J = 10.8, 4.7 Hz, 1H, Glc H4), 3.52 – 3.45 (m, 2H, Glc H2 & 
Glc H6), 3.39 (dd, J = 8.3, 6.7 Hz, 1H, Rha H5), 3.36 (s, 3H, Glc OMe), 1.50 (s, 3H, 
isopropylidene), 1.33 (s, 3H, isopropylidene), 1.26 – 1.24 (m, 3H, Rha H6 ).13C NMR (151 
MHz, CDCl3) δ 138.6, 138.0, 128.5, 128.4 , 128.1, 128.0, 127.6, 109.4 (Isopropylidene C), 
98.0 (Glc C1), 97.3 (Rha C1), 82.1 (Glc C3), 80.0 (Glc C2), 77.8 (Rha C3), 77.3 (Glc C4), 75.8 
(Rha C2), 75.2 (Benzyl CH2), 75.0 (Benzyl CH2), 73.7 (Benzyl CH2), 73.4 (Benzyl CH2), 69.7 
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(Glc C5), 66.7 (Rha C4), 65.9 (Glc C6), 55.2 (Glc OMe), 27.7 (Isopropylidene Me), 25.9 
(Isopropylidene Me), 17.8 (Rha C6). HRMS m/z [M+Na]+ calcd for C37H46NaO10 673.2989, 
found 673.2991. 
Inhibition of anti-CR3-FITC antibody staining of human neutrophils and of anti-Dectin 
1-FITC antibody staining of mouse macrophages.   
    For fluorescent staining, anti-CR3-FITC antibodies (MN-41 donated by Drs. Allison Eddy 
and Alfred Michael of the University of Minnesota, Minneapolis, MN, and Rat anti Mouse 
Dectin-1 antibody labeled with FITC (purchased from AbD Serotec, Raleigh, NC) were 
employed. Either human neutrophils or mouse peritoneal macrophages were incubated with 
0.1 g.mL-1 of tested samples for 0.5 h on ice and washed. Subsequently, the cells were stained 
with antibodies on ice using standard techniques. After centrifugation of cells through a 3 mL 
cushion of 12% BSA in PBS, the cells were re-suspended in PBS containing 1% BSA and 10 
mM sodium azide. Cell cytometry was performed with a Becton Dickinson-LSRII instrument. 
The inhibition of CR3 receptor and Dectin-1 receptor staining was calculated as described.90 
Stimulation of phagocytosis 
The technique employing phagocytosis of synthetic polymeric microspheres was 
described earlier.91 9191Human cells (cell line RAW 264) were incubated in vitro with 10 
μg.mL-1 of tested samples for 24 h at 37 oC. After washing, 0.05 mL of 2-hydroxyethyl 
methacrylate particles (HEMA; 5x108/mL) was added. The test tubes were incubated at 37 oC 
for 1 h, with intermittent shaking. Smears were stained with Wright stain. Cells with three or 
more HEMA particles were considered positive. The insoluble glucan Glucan #300 used as 
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comparison standard was obtained from Yeast-derived insoluble Glucan #300 (>85% dry w/w 
basis) was purchased from Transfer Point (Columbia, SC, USA).  This glucan contains 96% 
carbohydrates and 2.1% proteins. Neutral sugar analysis confirmed 91.3% glucose and 8% 
mannose. Stimulation of pinocytosos was determined spectrophotometrically as described.92 
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ABSTRACT 
DESIGN AND SYNTHESIS OF OLIGO-(3,5-DITHIO-β-D-GLUCOPYRANOSIDE)  
AS β-(1→3)-GLUCAN MIMETICS 
                               by 
 XIAOXIAO LIAO 
December 2018 
Advisor:  Dr. David Crich 
Major:   Chemistry 
Degree:   Doctor of Philosophy 
      This dissertation presents the design and synthesis of oligo-(3,5-dithio-β-D-
glucopyranoside) as β-(1 → 3)-D-glucan mimetics. The synthesized dimeric, trimeric and 
tetrameric mimetics were tested for their binding affinities to Dectin-1 and CR3 and their 
abilities to activate phagocytosis and pinocytosis.  
      The first chapter gives an introduction of β-(1 → 3)-D-glucan. It gives an introduction 
about the structure and origin of β-(1 → 3)-D-glucan as well as the immunostimulating effect 
of natural β-(1 → 3)-D-glucan. The study of interaction between β-(1 → 3)-D-glucan and the 
receptors leads to a conclusion that the hydrophobicity of β-(1 → 3)-D-glucan is crucial to its 
immunostimulating effect. Based on this conclusion, we designed the oligo-(3,5-dithio-β-D-
glucopyranoside) as β-(1 → 3)-D-glucan mimetics. 
      The second chapter presents the synthesis study of oligo-(3,5-dithio-β-D-
glucopyranoside). After a brief introduction of the synthesis of S-linked oligosaccharide, we 
talked about the synthesis of the 3,5-dithio-glucopyranoside as the monosaccharide building 
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block. It presents the rearrangement product during the synthesis of 3,5-dithio-glucopyranoside 
and how to avoid the rearrangement to synthesize 3,5-dithio-glucopyranoside. After the 
monosaccharide synthesis, we talked about the S-glycosylation study of 3,5-dithio-
glucopyranoside and how to synthesize the oligo-(3,5-dithio-β-D-glucopyranoside). Finally, 
the biological study of synthesized dimeric, trimeric and tetrameric mimetics was presented, 
which includes their binding affinities to Dectin-1 and CR3 and their abilities to stimulate the 
phagocytosis and pinocytosis.  
      Chapter three introduces p-N,N-dimethylamino benzyl (PDMAB) protecting group as 
a new protecting group. The novelty of PDMAB protecting group is that the deprotection can 
be achieved by microwave irradiation without any additives. We talked about the installation 
of PDMAB group and its application in the NIS / TMSOTf promoted glycosylation.  
Finally, chapter four presents the experimental procedures of all the compound and the 
characterization data.  
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